<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">9NMCbqgqyh7WH5gr9YDFjSq</article-id>
      <article-id pub-id-type="other">00006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000400006</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200406</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000400006</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Compara&#231;&#227;o de biomarcadores inflamat&#243;rios entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com angina inst&#225;vel</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Huoya</surname>
            <given-names>Mar&#231;al de Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Penalva</surname>
            <given-names>Rafaela Andrade</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alves</surname>
            <given-names>S&#237;lber Rodrigues</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Feitosa</surname>
            <given-names>G&#237;lson Soares</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gadelha</surname>
            <given-names>Sandra</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ladeia</surname>
            <given-names>Ana Marice Teixeira</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff04"/>
        </contrib>
      </contrib-group>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Baiana Para o Desenvolvimento das Ci&#234;ncias</institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
        </addr-line>
        <institution content-type="orgname">Divis&#227;o de Cardiologia</institution>
        <institution content-type="orgdiv1">Hospital Santa Izabel </institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Funda&#231;&#227;o Oswaldo Cruz</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff04">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Universidade Federal da Bahia</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>4</issue>
      <fpage>283</fpage>
      <lpage>289</lpage>
      <history>
        <date date-type="accepted">
          <day>28</day>
          <month>01</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>17</day>
          <month>01</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>06</day>
          <month>10</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Poucos estudos compararam a atividade inflamat&#243;ria entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com s&#237;ndrome coronariana aguda, e ainda n&#227;o foi publicado nenhum somente com portadores de angina inst&#225;vel (AI). OBJETIVO: Este estudo teve dois objetivos. Em primeiro lugar, comparar os n&#237;veis s&#233;ricos de prote&#237;na C reativa (PCR) e interleucina - 6 (IL-6) em pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com angina inst&#225;vel (AI) para determinar se a diferen&#231;a na atividade inflamat&#243;ria justifica o pior progn&#243;stico nos pacientes diab&#233;ticos. Em segundo, avaliar a correla&#231;&#227;o entre os marcadores inflamat&#243;rios e o perfil metab&#243;lico em pacientes diab&#233;ticos e entre a resposta inflamat&#243;ria e os desfechos hospitalares, como morte, infarto agudo do mioc&#225;rdio, insufici&#234;ncia card&#237;aca congestiva e tempo de hospitaliza&#231;&#227;o. M&#201;TODOS: Estudo de coorte prospectivo de 90 pacientes consecutivos admitidos na Unidade de Dor Tor&#225;cica com angina inst&#225;vel. Os pacientes foram divididos em dois grupos: diab&#233;ticos e n&#227;o-diab&#233;ticos. Os n&#237;veis s&#233;ricos de PCR e IL-6, o perfil metab&#243;lico e a contagem de leuc&#243;citos foram obtidos na chegada ao hospital. RESULTADOS: Dos pacientes analisados, 42 (47%) eram diab&#233;ticos (idade 62 &#177; 9) e 48 (53%) n&#227;o eram diab&#233;ticos (idade 63 &#177; 12). N&#227;o foram encontradas diferen&#231;as entre a mediana da PCR (1,78 vs. 2,23 mg/l, p = 0,74) e da IL-6 (0 vs. 0 pg/ml, p = 0,31) entre os dois grupos. Houve uma correla&#231;&#227;o positiva entre PCR e colesterol total (rs = 0, 21, p = 0, 05), PCR e colesterol LDL (r s = 0,22, p = 0,04) e PCR e contagem de leuc&#243;citos (r s = 0,32, p = 0,02) nos dois grupos. Nenhuma associa&#231;&#227;o foi encontrada entre os marcadores inflamat&#243;rios e os desfechos hospitalares. CONCLUS&#195;O: N&#227;o encontramos diferen&#231;a na atividade inflamat&#243;ria entre os pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com AI, o que indica que esse quadro cl&#237;nico pode equilibrar a atividade inflamat&#243;ria entre os dois grupos e aumentar a concentra&#231;&#227;o de marcadores inflamat&#243;rios de fase aguda, independentemente do estado metab&#243;lico.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Aterosclerose</kwd>
        <kwd>diabetes mellitus</kwd>
        <kwd>inflama&#231;&#227;o</kwd>
        <kwd>angina pectoris</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>23</day>
        <month>06</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> CORONARIOPATIA AGUDA</p>
    <p>Compara&#231;&#227;o de biomarcadores inflamat&#243;rios entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com angina inst&#225;vel</p>
    <p>
      <bold>Mar&#231;al de Oliveira Huoya<sup>I</sup>; Rafaela Andrade Penalva<sup>II</sup>; S&#237;lber Rodrigues Alves<sup>II</sup>; G&#237;lson Soares Feitosa<sup>I</sup>; Sandra Gadelha<sup>III</sup>; Ana Marice Teixeira Ladeia<sup>II,IV</sup></bold>
    </p>
    <p><sup>I</sup>Divis&#227;o de Cardiologia - Hospital Santa Izabel, Salvador - Brasil </p>
    <p><sup>II</sup>Funda&#231;&#227;o Baiana Para o Desenvolvimento das Ci&#234;ncias, Salvador - Brasil </p>
    <p><sup>III</sup>Funda&#231;&#227;o Osvaldo Cruz, Salvador - Brasil </p>
    <p><sup>IV</sup>Faculdade de Medicina da Universidade Federal da Bahia, Salvador - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="cor">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> Poucos estudos compararam a atividade inflamat&#243;ria entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com s&#237;ndrome coronariana aguda, e ainda n&#227;o foi publicado nenhum somente com portadores de angina inst&#225;vel (AI). </p>
    <p><bold>OBJETIVO:</bold> Este estudo teve dois objetivos. Em primeiro lugar, comparar os n&#237;veis s&#233;ricos de prote&#237;na C reativa (PCR) e interleucina - 6 (IL-6) em pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com angina inst&#225;vel (AI) para determinar se a diferen&#231;a na atividade inflamat&#243;ria justifica o pior progn&#243;stico nos pacientes diab&#233;ticos. Em segundo, avaliar a correla&#231;&#227;o entre os marcadores inflamat&#243;rios e o perfil metab&#243;lico em pacientes diab&#233;ticos e entre a resposta inflamat&#243;ria e os desfechos hospitalares, como morte, infarto agudo do mioc&#225;rdio, insufici&#234;ncia card&#237;aca congestiva e tempo de hospitaliza&#231;&#227;o. </p>
    <p><bold>M&#201;TODOS:</bold> Estudo de coorte prospectivo de 90 pacientes consecutivos admitidos na Unidade de Dor Tor&#225;cica com angina inst&#225;vel. Os pacientes foram divididos em dois grupos: diab&#233;ticos e n&#227;o-diab&#233;ticos. Os n&#237;veis s&#233;ricos de PCR e IL-6, o perfil metab&#243;lico e a contagem de leuc&#243;citos foram obtidos na chegada ao hospital. </p>
    <p><bold>RESULTADOS:</bold> Dos pacientes analisados, 42 (47%) eram diab&#233;ticos (idade 62 &#177; 9) e 48 (53%) n&#227;o eram diab&#233;ticos (idade 63 &#177; 12). N&#227;o foram encontradas diferen&#231;as entre a mediana da PCR (1,78 <italic>vs</italic>. 2,23 mg/l, p = 0,74) e da IL-6 (0 <italic>vs.</italic> 0 pg/ml, p = 0,31) entre os dois grupos. Houve uma correla&#231;&#227;o positiva entre PCR e colesterol total (rs = 0, 21, p = 0, 05), PCR e colesterol LDL (r<sub>s</sub> = 0,22, p = 0,04) e PCR e contagem de leuc&#243;citos (r<sub>s</sub> = 0,32, p = 0,02) nos dois grupos. Nenhuma associa&#231;&#227;o foi encontrada entre os marcadores inflamat&#243;rios e os desfechos hospitalares. </p>
    <p><bold>CONCLUS&#195;O:</bold> N&#227;o encontramos diferen&#231;a na atividade inflamat&#243;ria entre os pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com AI, o que indica que esse quadro cl&#237;nico pode equilibrar a atividade inflamat&#243;ria entre os dois grupos e aumentar a concentra&#231;&#227;o de marcadores inflamat&#243;rios de fase aguda, independentemente do estado metab&#243;lico.</p>
    <p><bold>Palavras-chave:</bold> Aterosclerose / complica&#231;&#245;es, diabetes mellitus, inflama&#231;&#227;o / complica&#231;&#245;es, angina pectoris.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A aterosclerose &#233; a respons&#225;vel por 80% de todas as mortes em pacientes diab&#233;ticos<sup>1</sup>. Como as estimativas mostram que a preval&#234;ncia de diabetes dobrar&#225; at&#233; o ano de 2025, a incid&#234;ncia de doen&#231;a cardiovascular associada com diabetes aumentar&#225; substancialmente<sup>2</sup>.</p>
    <p>Comparados aos indiv&#237;duos n&#227;o-diab&#233;ticos, os pacientes diab&#233;ticos t&#234;m um risco de duas a quatro vezes maior de desenvolver doen&#231;a coronariana<sup>3</sup>, um risco duas vezes maior de mortalidade em curto prazo ap&#243;s infarto agudo do mioc&#225;rdio<sup>4,5</sup> e piores resultados quando submetidos &#224; angioplastia, com maior risco de reestenose. A atividade inflamat&#243;ria &#233; aumentada nos pacientes com diabetes tipo 1<sup>6</sup> e tipo 2, al&#233;m de ser fortemente associada ao risco de aterotrombose<sup>7</sup>.</p>
    <p>A prote&#237;na C reativa (PCR) &#233; o principal mediador da resposta da fase aguda. Essa prote&#237;na, derivada principalmente da bioss&#237;ntese hep&#225;tica dependente da IL-6, h&#225; muito &#233; considerada bastante est&#225;vel<sup>8</sup>. Os n&#237;veis de PCR aumentam rapidamente em rea&#231;&#227;o a trauma, inflama&#231;&#227;o e infec&#231;&#227;o, diminuindo da mesma forma quando esses problemas desaparecem<sup>9</sup>. Por esse motivo, a dosagem de PCR &#233; comumente usada para o monitoramento de v&#225;rios estados inflamat&#243;rios. A s&#237;ntese de PCR &#233; controlada principalmente pela IL-6<sup>10</sup>, que, por sua vez, &#233; secretada por leuc&#243;citos ativados, adip&#243;citos e c&#233;lulas endoteliais<sup>11</sup>.</p>
    <p>O aumento nos n&#237;veis de prote&#237;na C reativa (PCR) e interleucina 6 (IL-6) est&#225; associado com uma maior incid&#234;ncia de eventos card&#237;acos adversos em pacientes com s&#237;ndromes coronarianas agudas, assim como em pacientes submetidos a implante de <italic>stent </italic>coronariano<sup>12</sup>. Aggarwal e cols.<sup>13</sup> constataram que os n&#237;veis de PCR eram mais elevados (o dobro) em portadores de s&#237;ndrome coronariana aguda diab&#233;ticos do que em n&#227;o-diab&#233;ticos, antes e depois da coloca&#231;&#227;o do <italic>stent </italic>coronariano.</p>
    <p>Poucos estudos publicados at&#233; hoje compararam a atividade inflamat&#243;ria entre portadores de s&#237;ndrome coronariana aguda diab&#233;ticos e n&#227;o-diab&#233;ticos, e nenhum deles incluiu apenas pacientes com angina inst&#225;vel. Este estudo tem como objetivo comparar os n&#237;veis de prote&#237;na C reativa ultra-sens&#237;vel (PCR-us), IL-6 e a contagem de leuc&#243;citos entre os pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos para determinar se a exist&#234;ncia de diferen&#231;as na atividade inflamat&#243;ria pode explicar a pior evolu&#231;&#227;o cl&#237;nica ou os resultados de procedimentos em pacientes diab&#233;ticos com s&#237;ndrome coronariana aguda. </p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Delineamento do estudo</bold>
    </p>
    <p>Este estudo observacional e de corte transversal, com compara&#231;&#227;o entre grupos, foi realizado na Unidade de Dor Tor&#225;cica do Hospital Santa Izabel entre fevereiro e outubro de 2005. O estudo incluiu 90 pacientes consecutivos com angina inst&#225;vel, independentemente de idade ou sexo, que foram classificados em dois grupos: diab&#233;ticos e n&#227;o-diab&#233;ticos. &#192; admiss&#227;o, todos os pacientes foram imediatamente examinados por um cardiologista, que mediu a freq&#252;&#234;ncia card&#237;aca, a press&#227;o arterial e a oximetria de pulso. Todos receberam 200 mg de aspirina e foram submetidos a um eletrocardiograma de 12 deriva&#231;&#245;es. Al&#233;m disso, foram coletadas amostras de sangue para an&#225;lise laboratorial no pronto-socorro, com um retardo m&#225;ximo de 15 minutos.</p>
    <p>Os crit&#233;rios de inclus&#227;o no estudo foram: idade acima de 30 anos, indiv&#237;duos de ambos os sexos, angina inst&#225;vel e tempo entre in&#237;cio da dor tor&#225;cica e interna&#231;&#227;o de no m&#225;ximo 12 horas. </p>
    <p>A angina inst&#225;vel foi definida de acordo com a classifica&#231;&#227;o de Braunwald<sup>14</sup>, e apenas os pacientes com classe IIIB foram inclu&#237;dos no estudo. </p>
    <p>Foram exclu&#237;dos os pacientes com infarto do mioc&#225;rdio recente (menos de quatro semanas), cardiomiopatia dilatada ou chag&#225;sica, fibrila&#231;&#227;o atrial, valvopatia, n&#237;veis s&#233;ricos elevados de marcadores de necrose mioc&#225;rdica at&#233; 12 horas ap&#243;s a interna&#231;&#227;o (troponina T &gt; 0,1 &#181;g/ml e <bold>fra&#231;&#227;o MB da</bold> creatinofosfoquinase &gt; <bold>4,94 &#181;g/ml com curva caracter&#237;stica</bold> de eleva&#231;&#227;o e queda), tromboembolia, cirurgia, angioplastia coronariana transluminal percut&#226;nea (ACTP) nas quatro semanas anteriores, doen&#231;a inflamat&#243;ria ou neopl&#225;sica, insufici&#234;ncia renal cr&#244;nica e febre na &#250;ltima semana.</p>
    <p>Os pacientes foram classificados de acordo com idade, sexo, dor precordial no momento da interna&#231;&#227;o, escore de risco TIMI, dura&#231;&#227;o do diabetes, hipertens&#227;o, tabagismo, doen&#231;a arterial coronariana pr&#233;via, angioplastia coronariana transluminal percut&#226;nea (ACTP), cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica (CRM), infarto do mioc&#225;rdio pr&#233;vio, dislipidemia, dura&#231;&#227;o da dor tor&#225;cica, tempo transcorrido entre o in&#237;cio da dor tor&#225;cica e a interna&#231;&#227;o (delta T em minutos), consumo de &#225;lcool, hist&#243;ria familiar de doen&#231;a arterial coronariana precoce e &#237;ndice de massa corporal, calculado por meio do peso e da altura declarados pelos pacientes. Foram ainda registrados o tratamento realizado antes da inclus&#227;o no estudo e o tratamento hospitalar, realizado de acordo com o protocolo de rotina da Unidade de Dor Tor&#225;cica.</p>
    <p>O diabetes foi definido por glicemia ocasional <underline>&gt;</underline> 200 mg/dL ou glicemia em jejum <underline>&gt;</underline> 126mg/dL, uso de hipoglicemiantes orais ou insulina ou hist&#243;ria relatada pelo paciente<sup>15</sup>. </p>
    <p>A dislipidemia foi definida por n&#237;veis lip&#237;dicos elevados de acordo com o <italic>III National Cholesterol Education Program</italic><sup>16</sup> ou pelo uso de medicamentos hipolipemiantes.</p>
    <p>Morte; infarto agudo do mioc&#225;rdio (IAM), caracterizado por n&#237;veis de troponina-T <underline>&gt;</underline> 0,1 &#181;g/ml e de CK-MB massa <underline>&gt;</underline> 5,0&#181;g/ml com curva caracter&#237;stica de eleva&#231;&#227;o e queda; insufici&#234;ncia card&#237;aca congestiva (ICC) antes da alta e tempo de interna&#231;&#227;o foram considerados desfechos hospitalares. </p>
    <p>O Comit&#234; de Bio&#233;tica local do nosso centro aprovou o protocolo do estudo, e todos os pacientes forneceram um termo de consentimento livre e esclarecido.</p>
    <p>
      <bold>Avalia&#231;&#227;o laboratorial</bold>
    </p>
    <p>No momento da interna&#231;&#227;o, amostras de sangue venoso foram obtidas antes da administra&#231;&#227;o intravenosa de qualquer medicamento (exceto aspirina, de acordo com o protocolo da Unidade de Dor Tor&#225;cica), com uma demora de no m&#225;ximo 15 minutos. Amostras de plasma identificadas foram armazenadas a -85 &#186;C. A PCR foi dosada por meio de ensaio imunonefelom&#233;trico hipersens&#237;vel com part&#237;culas de l&#225;tex, em um analisador BN II (<italic>Dade Bering</italic>, Newark, Del), no Laborat&#243;rio de An&#225;lises Cl&#237;nicas. O limite inferior de detec&#231;&#227;o da prote&#237;na C reativa foi 1,3mg/l. O coeficiente de varia&#231;&#227;o entre ensaios foi de 2,2%, e o coeficiente intra-ensaio, 2,9%. </p>
    <p>A concentra&#231;&#227;o plasm&#225;tica de IL-6 foi determinada por meio de ensaio imunoenzim&#225;tico (Quantikine human IL-6, R&amp;D Systems, Minneapolis, MN) na Funda&#231;&#227;o Osvaldo Cruz (FioCruz). O limite inferior de detec&#231;&#227;o da interleucina-6 foi menos de 0,9 pg/ml. O coeficiente de varia&#231;&#227;o entre ensaios foi de 6,4%, e o coeficiente intra-ensaio, 4,2%.</p>
    <p>Os n&#237;veis plasm&#225;ticos de glicose, triglic&#233;rides, colesterol total e colesterol HDL foram determinados por meio de ensaios enzim&#225;ticos colorim&#233;tricos (reagentes da <italic>Boehringer Mannheim Diagnostics</italic>, Mannheim, Alemanha). Nos indiv&#237;duos com n&#237;veis plasm&#225;ticos de triglic&#233;rides abaixo de 400 mg/dl, o colesterol LDL era calculado de acordo com a f&#243;rmula de Friedewald. Quando os n&#237;veis de triglic&#233;rides estavam acima de 400 mg/dl, o colesterol LDL era dosado pelo m&#233;todo enzim&#225;tico em um analisador autom&#225;tico Hitachi 902 (Boehringer Mannheim, Mannheim, Alemanha).</p>
    <p>Os n&#237;veis de HbA<sub>1c </sub>foram determinados por imunoensaio imunoturbidim&#233;trico (<italic>Roche DiagnosticsGmbH</italic>, D-68298, Mannheim), com valores normais entre 4,5 e 6,1 %. </p>
    <p>
      <bold>An&#225;lises estat&#237;sticas</bold>
    </p>
    <p>O estudo foi delineado para ter um poder estat&#237;stico de 80% na detec&#231;&#227;o de uma diferen&#231;a duas vezes maior no valor da prote&#237;na C reativa entre os dois grupos. Para obter essa diferen&#231;a foram usados o valor m&#233;dio de 2,8 mg/L e um desvio-padr&#227;o de 4,48 mg/L<sup>17</sup>. Levando-se em considera&#231;&#227;o um erro tipo I de 0,05 e um erro tipo II de 0,20, foram necess&#225;rios 80 pacientes.</p>
    <p>As concentra&#231;&#245;es de prote&#237;na C reativa e IL-6 foram apresentadas como mediana e intervalo interquart&#237;lico. As caracter&#237;sticas basais foram comparadas pelo teste do qui-quadrado ou teste exato de Fisher para vari&#225;veis categ&#243;ricas e pelo teste da soma dos postos de Wilcoxon ou teste <italic>t</italic> de Student para vari&#225;veis cont&#237;nuas. Testes n&#227;o-param&#233;tricos foram usados para comparar a PCR-us e a IL-6 entre os grupos (teste U de Mann-Whitney) e determinar correla&#231;&#245;es (teste<italic> p</italic> de Spearman). Todos os valores de <italic>p</italic> s&#227;o bicaudais, e valores inferiores a 0,05 foram considerados estatisticamente significantes.</p>
    <p>Os dados foram analisados com aux&#237;lio do programa estat&#237;stico SPSS (vers&#227;o 10.0, SPSS Inc., Chicago, Illinois, EUA).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Caracter&#237;sticas iniciais</bold>
    </p>
    <p>De fevereiro a outubro de 2005, 117 pacientes consecutivos foram internados em um hospital cardiol&#243;gico de n&#237;vel terci&#225;rio. Foram exclu&#237;dos 24 pacientes que apresentaram eleva&#231;&#227;o dos marcadores s&#233;ricos card&#237;acos at&#233; 12 horas ap&#243;s a interna&#231;&#227;o, um paciente com cardiomiopatia chag&#225;sica, um paciente com dor tor&#225;cica ap&#243;s ingest&#227;o de bebida alco&#243;lica e um paciente com doen&#231;a renal cr&#244;nica. Tr&#234;s dos 24 pacientes exclu&#237;dos eram diab&#233;ticos. Noventa indiv&#237;duos que preenchiam os crit&#233;rios de inclus&#227;o foram estudados. A m&#233;dia de idade dos pacientes era 62 &#177; 9 (34 a 87), 42 eram diab&#233;ticos e 48 n&#227;o eram diab&#233;ticos. </p>
    <p>A <xref ref-type="table" rid="tab1">tabela 1</xref> mostra as caracter&#237;sticas cl&#237;nicas e laboratoriais iniciais dos pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos. N&#227;o houve diferen&#231;as nas caracter&#237;sticas cl&#237;nicas iniciais entre os dois grupos, exceto por maior press&#227;o arterial sist&#243;lica (158 &#177; 31 <italic>vs.</italic> 143 &#177; 31 mm Hg, p = 0,02) e freq&#252;&#234;ncia card&#237;aca (75 &#177; 15 vs. 67 &#177; 12 batimentos/minuto, <italic>p</italic> = 0,01) nos pacientes diab&#233;ticos no momento da interna&#231;&#227;o. O tempo m&#233;dio transcorrido entre o in&#237;cio da dor tor&#225;cica e a interna&#231;&#227;o na Unidade de Dor Tor&#225;cica foi semelhante para os pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos (4,3 &#177; 0,6 <italic>vs.</italic> 4,0 &#177; 5,0h, <italic>p</italic> = 0,83). N&#227;o foram observadas diferen&#231;as em rela&#231;&#227;o ao tratamento pr&#233;vio entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos, exceto pelo uso de medicamentos hipoglicemiantes e insulina. </p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt01.jpg"/></table-wrap>
    <p>O tempo transcorrido entre a &#250;ltima refei&#231;&#227;o e a coleta das amostras de sangue tamb&#233;m foi semelhante nos dois grupos (4,9 &#177; 3,1 <italic>vs.</italic> 5,0 &#177; 3,3h, <italic>p</italic> = 0,95). N&#227;o houve diferen&#231;as nas caracter&#237;sticas laboratoriais entre os dois grupos, exceto por n&#237;veis mais elevados de glicemia no momento da interna&#231;&#227;o (178 &#177; 78 <italic>vs.</italic> 105 &#177; 27mg/dl, <italic>p</italic> &lt; 0,001), de glicemia em jejum (130 &#177; 40 <italic>vs.</italic> 96 &#177;12 mg/dl, <italic>p </italic>&lt; 0,001) e de HbA<sub>1c</sub> (6,3 &#177; 4,2 <italic>vs. </italic>3,4 &#177; 1,2 %, <italic>p</italic> &lt; 0,001).</p>
    <p>
      <bold>Marcadores inflamat&#243;rios</bold>
    </p>
    <p>Na popula&#231;&#227;o do estudo como um todo, a mediana da PCR-<bold>us, da IL-6 e da contagem de leuc&#243;citos foi, respectivamente</bold>, 2 mg/L (intervalo interquart&#237;lico 0,8 - 4,7 mg/L), 0 pg/ml (intervalo interquart&#237;lico 0 - 0 pg/ml) e 7.900/mm<sup>3</sup> (intervalo interquart&#237;lico 6327 - 9895 l/mm<sup>3</sup>).</p>
    <p>A <bold>mediana das concentra&#231;&#245;es de PCR-us (1,78 mg/L </bold><italic>vs.</italic> 2,23 mg/L, <italic>p</italic> = 0,74) e IL-6 (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,31) e da contagem de leuc&#243;citos (8.245/mm<sup>3</sup><italic>vs.</italic> 7520/mm<sup>3</sup>, p = 0,74) foram semelhantes entre os indiv&#237;duos diab&#233;ticos e n&#227;o-diab&#233;ticos (<xref ref-type="table" rid="tab2">Tabela 2</xref>).</p>
    <table-wrap id="tab2">
      <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt02.jpg"/></table-wrap>
    <p>N&#227;o foi observada nenhuma diferen&#231;a entre os grupos quando eles foram analisados de acordo com tr&#234;s faixas de PCR (&lt; 1 mg/L, 1 a 3 mg/L e &gt; 3 mg/L): &lt; 1 mg/L (16% <italic>vs.</italic> 14%, <italic>p</italic> = 0,5), 1 a 3 mg/L (10% <italic>vs.</italic> 18%, <italic>p</italic> = 0,32) e &gt; 3 mg/L (14% <italic>vs. </italic>14%, <italic>p</italic> = 0,7). Os grupos de pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos tamb&#233;m tiveram distribui&#231;&#227;o semelhante quando analisados em rela&#231;&#227;o aos quartis: &lt; 0,8 mg/L (15% <italic>vs.</italic> 12%, <italic>p</italic> = 0,36), 0,81 a 2,04 mg/L (12% <italic>vs. </italic>13%, <italic>p</italic> = 0,95), 2,05 a 4,7 mg/L (8% <italic>vs.</italic> 16%, <italic>p</italic> = 0,12) e &gt; 4,7 mg/L (14% <italic>vs.</italic> 13%, <italic>p</italic> = 0,66).</p>
    <p>Quando os n&#237;veis de IL-6 foram analisados como vari&#225;veis categ&#243;ricas (0 pg/mL = n&#227;o e &gt; 0 pg/mL = sim), os resultados positivos foram semelhantes nos dois grupos (17% <italic>vs.</italic> 8%, <italic>p</italic> = 0,12).</p>
    <p>Em toda a popula&#231;&#227;o do estudo, os n&#237;veis de prote&#237;na C reativa foram positivamente correlacionados com os n&#237;veis de colesterol total (r<sub>s</sub> = 0,21,<italic> p</italic> = 0,05), os n&#237;veis de colesterol LDL (r<sub>s</sub> = 0,22, <italic>p</italic> = 0,04) e a contagem de leuc&#243;citos (r<sub>s</sub> = 0,32, <italic>p</italic> = 0,02).</p>
    <p>
      <bold>Desfechos hospitalares</bold>
    </p>
    <p>A m&#233;dia do tempo de hospitaliza&#231;&#227;o foi de 12 dias, com mediana de 7 dias (2 a 125 dias).</p>
    <p>Durante o per&#237;odo de interna&#231;&#227;o, n&#227;o houve diferen&#231;as entre os pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos no que diz respeito &#224; ocorr&#234;ncia de insufici&#234;ncia card&#237;aca congestiva (5%<italic> vs.</italic> 0%, <italic>p</italic> = 0,21), infarto agudo do mioc&#225;rdio (5% <italic>vs.</italic> 2%, <italic>p</italic> = 0,60), morte (25 <italic>vs.</italic> 0%, <italic>p</italic> = 0,47) e mediana do tempo de hospitaliza&#231;&#227;o (8 dias <italic>vs.</italic> 7 dias, <italic>p</italic> = 0,44). Os desfechos combinados tamb&#233;m foram semelhantes nos dois grupos (12% <italic>vs. </italic>2%, <italic>p</italic> = 0,06, RR = 5,7; IC 95%, 0,7 a 56) (<xref ref-type="table" rid="tab3">Tabela 3</xref>). </p>
    <table-wrap id="tab3">
      <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt03.jpg"/></table-wrap>
    <p>Quando os indiv&#237;duos que tiveram eventos hospitalares foram comparados com os que n&#227;o tiveram eventos, a mediana de PCR-us foi semelhante em ambos os grupos para ICC (8,1 mg/L <italic>vs. </italic>2,4 mg/L, <italic>p</italic> = 0,47), IAM (7,8 mg/L <italic>vs.</italic> 1,7 mg/L, <italic>p</italic> = 0,81) e morte por causas cardiovasculares (5,66 mg/L <italic>vs. </italic>2,04 mg/L, <italic>p</italic> = 0,41). Nenhuma diferen&#231;a foi observada tamb&#233;m, respectivamente, na mediana da IL-6 e da contagem de leuc&#243;citos para ICC (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,58; 9.590 l/mm<sup>3</sup> v<italic>s.</italic> 7460 l/mm<sup>3</sup>, <italic>p</italic> = 0,53), IAM (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,58; 7.925 l/mm<sup>3</sup><italic>vs.</italic> 7.860 l/mm<sup>3</sup>, <italic>p</italic> = 0,5) e morte (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,70; 11.500 l/mm<sup>3</sup><italic>vs. </italic>7.900 l/mm<sup>3</sup>, <italic>p</italic> = 0,22).</p>
    <p>N&#227;o houve correla&#231;&#227;o entre o tempo de hospitaliza&#231;&#227;o e os n&#237;veis de PCR-us (r<sub>s</sub> = 0,02, <italic>p</italic> = 0,86), IL-6 (r<sub>s</sub> = 0,09, <italic>p</italic> = 0,44) ou contagem de leuc&#243;citos (r<sub>s</sub> = 0,21, <italic>p </italic>= 0, 85).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p> Poucos estudos cl&#237;nicos compararam os marcadores inflamat&#243;rios entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com s&#237;ndrome coronariana aguda, mas nenhum deles foi realizado exclusivamente com portadores de angina inst&#225;vel.</p>
    <p>Moreno e cols.<sup>18</sup> constataram que o tecido coronariano dos pacientes diab&#233;ticos tem maior quantidade de ateroma rico em lip&#237;dios, infiltra&#231;&#227;o de macr&#243;fagos e trombose subseq&#252;ente do que o tecido de pacientes n&#227;o-diab&#233;ticos, o que indica que portadores de diabetes melito s&#227;o mais vulner&#225;veis &#224; ruptura da placa e trombose. Os mesmos autores analisaram a patog&#234;nese da aterosclerose diab&#233;tica<sup>19</sup> e acreditam que os portadores de diabetes melito t&#234;m maior atividade inflamat&#243;ria do que a popula&#231;&#227;o em geral com aterosclerose. </p>
    <p>No entanto, neste estudo n&#227;o foram observadas diferen&#231;as nas concentra&#231;&#245;es de PCR-us e IL-6 entre pacientes com angina inst&#225;vel diab&#233;ticos e n&#227;o-diab&#233;ticos.</p>
    <p>Aggarwal e cols.<sup>13</sup> avaliaram a atividade inflamat&#243;ria medindo os n&#237;veis de PCR-us em 75 pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com s&#237;ndrome coronariana aguda antes, durante e depois da coloca&#231;&#227;o de <italic>stent</italic> coronariano. Esses autores conclu&#237;ram que os pacientes diab&#233;ticos com s&#237;ndrome coronariana aguda tinham maior atividade inflamat&#243;ria antes do procedimento, mas depois de 24 horas n&#227;o foram encontradas diferen&#231;as entre os pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos. Contudo, os autores n&#227;o inclu&#237;ram em sua metodologia informa&#231;&#245;es fundamentais que revelassem se a popula&#231;&#227;o do estudo era, de fato, portadora de s&#237;ndrome coronariana aguda. N&#227;o foram fornecidos dados sobre o tempo transcorrido desde o in&#237;cio da dor tor&#225;cica at&#233; a interna&#231;&#227;o ou at&#233; mesmo a coloca&#231;&#227;o de <italic>stent</italic> (primeira amostra de sangue). Al&#233;m disso, os autores inclu&#237;ram apenas pacientes com angina est&#225;vel e infarto agudo do mioc&#225;rdio sem supradesnivelamento do segmento ST, quando o fator necrose pode funcionar como uma vari&#225;vel de confus&#227;o<sup>20</sup>. Nem mesmo os valores de glicemia foram descritos, ao contr&#225;rio do nosso estudo, que usou um crit&#233;rio validado para definir diabetes.</p>
    <p>A an&#225;lise dos n&#237;veis de PCR entre os dois grupos mostrou que, antes da coloca&#231;&#227;o de <italic>stent</italic>, os pacientes diab&#233;ticos tinham o dobro de atividade inflamat&#243;ria dos n&#227;o-diab&#233;ticos. No entanto, depois da coloca&#231;&#227;o do <italic>stent</italic> coronariano (agress&#227;o endotelial) n&#227;o houve diferen&#231;a nas concentra&#231;&#245;es de PCR-us entre os dois grupos. Gottsauner e cols.<sup>21</sup> descobriram que n&#237;veis plasm&#225;ticos elevados da prote&#237;na C reativa, que persistem por 96 horas depois da implanta&#231;&#227;o do<italic> stent</italic>, podem refletir uma rea&#231;&#227;o inflamat&#243;ria prolongada ao implante de <italic>stent </italic>coronariano.</p>
    <p>O papel da agress&#227;o endotelial aguda como est&#237;mulo a uma rea&#231;&#227;o inflamat&#243;ria intensa tamb&#233;m pode estar presente na angina inst&#225;vel, justificando os nossos achados e refor&#231;ando, assim, os nossos resultados.</p>
    <p>&#201; interessante observar que, em nosso estudo, usamos uma metodologia bastante cuidadosa para incluir pacientes com angina inst&#225;vel. Todos os indiv&#237;duos foram rigorosamente classificados por meio de crit&#233;rios validados, como angina inst&#225;vel, para evitar a interfer&#234;ncia do fator necrose como uma vari&#225;vel de confus&#227;o, sendo internados no pronto-socorro card&#237;aco indiv&#237;duos com dor t&#237;pica e idade m&#233;dia superior a 60 anos com uma probabilidade p&#243;s-teste acima de 80 % para SCA. Al&#233;m disso, no final do estudo a presen&#231;a de doen&#231;a coronariana ateroscler&#243;tica foi confirmada em 94% dos pacientes por meio de cineangiocoronariografia. Por fim, a homogeneidade entre os grupos foi demonstrada pela aus&#234;ncia de diferen&#231;as estatisticamente significantes nas caracter&#237;sticas cl&#237;nicas iniciais.</p>
    <p>Nossos achados com diferen&#231;as estatisticamente significantes (PAS e FC) podem ser explicados pela tend&#234;ncia de uma maior preval&#234;ncia de dor tor&#225;cica a admiss&#227;o no grupo de pacientes diab&#233;ticos contrariando o conceito original<sup>22</sup> que ali&#225;s tem sido atualmente bastante questionado<sup>23</sup>. </p>
    <p>Ao contr&#225;rio do nosso estudo, Sanchez e cols.<sup>24</sup> observaram que os pacientes diab&#233;ticos com s&#237;ndrome coronariana aguda sem supradesnivelamento do segmento ST apresentavam maior atividade inflamat&#243;ria do que os n&#227;o-diab&#233;ticos. No entanto, a contagem de leuc&#243;citos dos pacientes diab&#233;ticos foi mais elevada do que a dos n&#227;o-diab&#233;ticos, e os autores n&#227;o inclu&#237;ram nenhum instrumento para detectar processos infecciosos assintom&#225;ticos, principalmente em mulheres diab&#233;ticas<sup>25</sup>. Em nosso estudo, todos os pacientes foram submetidos a exames de urina e explora&#231;&#227;o das vias a&#233;reas, inclusive o conduto auditivo, para a exclus&#227;o de infec&#231;&#245;es assintom&#225;ticas. Al&#233;m disso, n&#227;o houve diferen&#231;a na contagem de leuc&#243;citos obtida no momento da interna&#231;&#227;o entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos, o que indica n&#227;o haver diferen&#231;as no quadro inflamat&#243;rio pr&#233;vio em decorr&#234;ncia de um processo infeccioso sist&#234;mico. Sanchez tamb&#233;m n&#227;o descreveu a glicemia no momento da interna&#231;&#227;o, a glicemia em jejum e o perfil lip&#237;dico em seu estudo.</p>
    <p> &#201; importante ressaltar que o estado metab&#243;lico do diabetes caracterizado por hiperglicemia e dislipidemia est&#225; associado com les&#227;o endotelial e, conseq&#252;entemente, aumento nos n&#237;veis dos marcadores inflamat&#243;rios<sup>19,26,27</sup>.</p>
    <p>No que diz respeito &#224; correla&#231;&#227;o positiva entre as concentra&#231;&#245;es de PCR-us e a contagem de leuc&#243;citos, Danesh e cols.<sup>28</sup> descreveram uma forte associa&#231;&#227;o entre a contagem de leuc&#243;citos e o desenvolvimento de doen&#231;a arterial coronariana. Stewart e cols.<sup>29</sup> observaram uma maior redu&#231;&#227;o da mortalidade associada ao uso de pravastatina nos pacientes que apresentaram valores mais elevados de contagem de leuc&#243;citos no momento da interna&#231;&#227;o.</p>
    <p>Neste estudo, quando analisamos todos os pacientes com angina inst&#225;vel, observamos uma fraca correla&#231;&#227;o entre PCR-us e colesterol total e colesterol LDL, por&#233;m superior &#224; relatada por estudos anteriores<sup>30,31</sup> que n&#227;o inclu&#237;ram pacientes com s&#237;ndrome coronariana aguda.</p>
    <p>N&#227;o observamos maior incid&#234;ncia de desfechos hospitalares entre pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos, apesar dos dados relatados na literatura<sup>32</sup>, provavelmente em conseq&#252;&#234;ncia do menor per&#237;odo de acompanhamento (mediana de 8 dias) e do pequeno n&#250;mero de pacientes (amostra pequena) para encontrar mais desfechos hospitalares, como ICC, IAM e morte (poder reduzido) em pacientes com angina inst&#225;vel.</p>
    <p>Outra limita&#231;&#227;o do nosso estudo foi o fato de que o tempo m&#233;dio entre o in&#237;cio da dor tor&#225;cica e a interna&#231;&#227;o no pronto-socorro (4 horas) at&#233; a coleta das amostras de sangue para medir os n&#237;veis de PCR-us pode ter sido insuficiente para a detec&#231;&#227;o de processo inflamat&#243;rio em andamento. Entretanto, isso n&#227;o explicaria os resultados semelhantes de PCR-us entre os dois grupos.</p>
    <p>Nossos achados indicam que os eventos envolvidos em um quadro de s&#237;ndrome coronariana aguda, como angina inst&#225;vel, propiciam uma resposta inflamat&#243;ria importante, por&#233;m semelhante, entre diab&#233;ticos e n&#227;o-diab&#233;ticos. Isso nos leva a crer que a resposta inflamat&#243;ria resultante de uma s&#237;ndrome coronariana aguda &#233; mais intensa e aguda do que a resposta inflamat&#243;ria resultante do diabetes, em que o processo &#233; mais lento e cont&#237;nuo e a agress&#227;o endotelial &#233; duradoura. Outra possibilidade &#233; de que o uso de estatina (que no nosso estudo foi semelhante em pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos) pode ser mais eficaz em pacientes diab&#233;ticos, j&#225; que foi descrito um efeito antiinflamat&#243;rio mais intenso em indiv&#237;duos com maior atividade inflamat&#243;ria<sup>29</sup>. &#201; importante frisar que os nossos pacientes diab&#233;ticos foram bem controlados (HbA<sub>1c </sub>m&#233;dia = 6,3%) e que esse achado pode diminuir o impacto da hiperglicemia na agress&#227;o endotelial.</p>
    <p>Em rela&#231;&#227;o a todos os pontos que discutimos em nosso estudo, algumas quest&#245;es t&#234;m de ser respondidas. Por exemplo, as caracter&#237;sticas inflamat&#243;rias observadas no diabetes e na s&#237;ndrome coronariana aguda s&#227;o diferentes? Existe algum modo de avaliar isso? A estatina &#233; mais eficaz em pacientes diab&#233;ticos do que em n&#227;o-diab&#233;ticos? Essa maior efic&#225;cia poderia explicar a igualdade da atividade inflamat&#243;ria entre os grupos com s&#237;ndrome coronariana aguda inclu&#237;dos no estudo? A rea&#231;&#227;o inflamat&#243;ria na s&#237;ndrome coronariana aguda &#233; t&#227;o intensa que poderia equilibrar a atividade inflamat&#243;ria dos pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos?</p>
    <p>Nossos achados nos permitem concluir que a atividade inflamat&#243;ria &#233; semelhante em pacientes diab&#233;ticos e n&#227;o-diab&#233;ticos com angina inst&#225;vel. Nesses pacientes, a PCR-us apresentou uma correla&#231;&#227;o positiva com o colesterol total e LDL, bem como com a contagem de leuc&#243;citos. Esses achados ainda ressaltam a import&#226;ncia da PCR como um marcador de agress&#227;o endotelial na s&#237;ndrome coronariana aguda, assim como o aspecto multifatorial do processo de aterotrombose. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado pela Funda&#231;&#227;o de Amparo a Pesquisa do estado da Bahia (FAPESB).</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de disserta&#231;&#227;o de Mestrado de Mar&#231;al de Oliveira Huoya pela Escola Bahiana de Medicina e Sa&#250;de P&#250;blica-FBDC.</p>
    <p>
      <fn id="cor" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Dr. Mar&#231;al de Oliveira Huoya </p>
        <p> Pra&#231;a Almeida Couto, 500 - 40.000-000 </p>
        <p> Salvador, BA - Brasil. </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="mohuoya@cardiol.br">mohuoya@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 06/10/07; revisado recebido em 17/01/08; aceito em 28/01/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Roffi M; Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2004; 25 (3): 190-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>190</fpage>
          <lpage>8</lpage>
          <issue>3</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Roffi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Topol</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence numerical estimates, and projections. Diabetes Care. 1998; 21: 1414-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Global burden of diabetes, 1995-2025: prevalence numerical estimates, and projections</article-title>
          <source>Diabetes Care.</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1414</fpage>
          <lpage>31</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Aubert</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Wilson PWF, Kannel WB. Epidemiology of hyperglycemia and atherosclerosis. In: Ruderman N, Williamson J, Brownlee M. (eds.) Hyperglycemia, diabetes, and vascular disease. New York: Oxford University Press; 1992. p. 21-9.</mixed-citation>
        <element-citation publication-type="book">
          <source>Hyperglycemia, diabetes, and vascular disease</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>21</fpage>
          <lpage>9</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>PWF</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Ruderman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brownlee</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996; 28: 1661-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1661</fpage>
          <lpage>9</lpage>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Woodfield</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Lundergan</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Reiner</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Greenhouse</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rohrbeck</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. West Ne, RuyGrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neil WW, et al. Clinical and angiographic predictor of restenosis after stent deployment in diabetic patients. Circulation. 2004; 109 (7): 867-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and angiographic predictor of restenosis after stent deployment in diabetic patients</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>867</fpage>
          <lpage>73</lpage>
          <issue>7</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>West Ne</surname>
            </name>
            <name>
              <surname>RuyGrok</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Disco</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Lindeboom</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>O'Neil WW</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, et al. Plasma concentration of C-reactive protein is increased in type-I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999; 42: 351-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma concentration of C-reactive protein is increased in type-I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation</article-title>
          <source>Diabetologia</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>351</fpage>
          <lpage>7</lpage>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schalkwijk</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Poland</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>van Dijk</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Emeis</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Drager</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Jager A, Van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. Von Willebran factor, C-reactive protein and 5-year mortality in diabetic and non-diabetic subjects: the Horn Study. Arterioscler Thromb Vasc Biol. 1999; 19: 3071-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Von Willebran factor, C-reactive protein and 5-year mortality in diabetic and non-diabetic subjects: the Horn Study</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>3071</fpage>
          <lpage>8</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jager</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Hinsbergh</surname>
              <given-names>VW</given-names>
            </name>
            <name>
              <surname>Kostense</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Emeis</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Yudkin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Nijpels</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Rifai N, Ridker PM. Population dsistributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem. 2003; 49: 666-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Population dsistributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation</article-title>
          <source>Clin Chem</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>666</fpage>
          <lpage>9</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rifai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32: 274-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Function of C-reactive protein</article-title>
          <source>Ann Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>274</fpage>
          <lpage>8</lpage>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Du Clos</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990; 265: 621-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interleukin-6 and the acute phase response</article-title>
          <source>Biochem J</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>621</fpage>
          <lpage>36</lpage>
          <volume>265</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Heinrich</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Castell</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Andus</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997; 350: 430-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic infections and coronary heart disease: is there a link?</article-title>
          <source>Lancet</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>430</fpage>
          <lpage>6</lpage>
          <volume>350</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Peto</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999; 34: 1512-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1512</fpage>
          <lpage>21</lpage>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Buffon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Liuzzo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Biasucci</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Pasqualetti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ramazzotti</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rebuzzi</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Comparison of inflammatory markers with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol. 2003; 92: 924-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of inflammatory markers with diabetes mellitus versus those without before and after coronary arterial stenting</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>924</fpage>
          <lpage>9</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aggarwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Sobel</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Dauerman</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Braunwald E. Unstable angina: a classification. Circulation. 1989; 80: 410-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Unstable angina: a classification</article-title>
          <source>Circulation</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>410</fpage>
          <lpage>4</lpage>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Kehoe R, Wu SY, Leske MC, Chylack LT Jr. Comparing self-reported and physician reported medical history. Am J Epidemiol. 1994; 139 (8): 813-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparing self-reported and physician reported medical history</article-title>
          <source>Am J Epidemiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>813</fpage>
          <lpage>8</lpage>
          <issue>8</issue>
          <volume>139</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kehoe</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Leske</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Chylack Jr</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-421.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>3143</fpage>
          <lpage>421</lpage>
          <volume>106</volume>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Schulze MB, Rifai N, Rimm EB, Stampfer MJ, Li T, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004; 27: 889-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>C-reactive protein and incident cardiovascular events among men with diabetes</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>889</fpage>
          <lpage>94</lpage>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schulze</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Rifai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rimm</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Stampfer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>FB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000; 102: 2180-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>2180</fpage>
          <lpage>4</lpage>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Murcia</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Palacios</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004; 44: 2293-300.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New aspects in the pathogenesis of diabetic atherothrombosis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2293</fpage>
          <lpage>300</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease: cause or effect? J Am Coll Cardiol. 2005; 46: 1496-502.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>C-reactive protein increase in unstable coronary disease: cause or effect?</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1496</fpage>
          <lpage>502</lpage>
          <volume>46</volume>
          <person-group person-group-type="author">
            <name>
              <surname>De Servi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mariani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mariani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mazzone</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, et al. Eur Heart J. 2000; 21: 1152-8.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Eur Heart J.</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1152</fpage>
          <lpage>8</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gottsauner-Wolf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zasmeta</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hornykewycz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nikfardjam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stepan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wexberg</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Bradley RF, Schonfield A. Diminished pain in diabetic patients with acute myocardial infarction. Geriatrics. 1962; 17: 322-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diminished pain in diabetic patients with acute myocardial infarction</article-title>
          <source>Geriatrics</source>
          <date>
            <year>1962</year>
          </date>
          <fpage>322</fpage>
          <lpage>6</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bradley</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Schonfield</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Airaksinen KEJ. Silent coronary artery disease in diabetes: a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia. 2001; 44: 259-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Silent coronary artery disease in diabetes: a feature of autonomic neuropathy or accelerated atherosclerosis?</article-title>
          <source>Diabetologia</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>259</fpage>
          <lpage>66</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Airaksinen</surname>
              <given-names>KEJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Sanchez PL, Morinigo JL, Pabon P, Martin F, Piedra I, Palacios IF, et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart. 2004; 90: 264-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome</article-title>
          <source>Heart</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>264</fpage>
          <lpage>9</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Morinigo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pabon</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Piedra</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Palacios</surname>
              <given-names>IF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002; 113 (Suppl. 1A): 80S-84S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Urinary tract infections in patients with diabetes</article-title>
          <source>Am J Med.</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>80S</fpage>
          <lpage>84S</lpage>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stapleton</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care. 2003; 26: 2165-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2165</fpage>
          <lpage>73</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schram</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Chaturvedi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schalkwijk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giorgino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ebeling</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fuller</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Prateley RE, Tataranni PA. Humoral markers of inflammation and endhotelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis. 2002; 161: 233-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Humoral markers of inflammation and endhotelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians</article-title>
          <source>Atherosclerosis</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>233</fpage>
          <lpage>42</lpage>
          <volume>161</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weyer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yudkin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Stehouwer</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Schalkwijk</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Prateley</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Tataranni</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA. 1998; 279: 1477-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease</article-title>
          <source>JAMA</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1477</fpage>
          <lpage>82</lpage>
          <volume>279</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Appleby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Peto</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Stewart RAH, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, et al. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation. 2005; 111: 1756-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>White blood cell count predicts reduction in coronary heart disease mortality with pravastatin</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1756</fpage>
          <lpage>62</lpage>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>RAH</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Kirby</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Heritier</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Simes</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Nestel</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285: 2481-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2481</fpage>
          <lpage>5</lpage>
          <volume>285</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Stampfer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Rifai</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Ridker PM, Rifai N, Rose L, Buring J, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1557</fpage>
          <lpage>65</lpage>
          <volume>347</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Rifai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Buring</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Brogan GX, Peterson ED, Mulgund J, Bhatt DL, Ohman EM, Gibler WB, et al. Treatment disparities in the care of patients with and without diabetes presenting with non-ST segment elevation acute coronary syndromes. Diabetes Care. 2006; 29: 9-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treatment disparities in the care of patients with and without diabetes presenting with non-ST segment elevation acute coronary syndromes</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>9</fpage>
          <lpage>14</lpage>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brogan</surname>
              <given-names>GX</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Mulgund</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Ohman</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gibler</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Comparison of inflammatory biomarkers between diabetic and non-diabetic patients with unstable angina</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Studies comparing inflammatory activity between diabetic and non-diabetic individuals with acute coronary syndrome are scarce, and none including only patients with unstable angina (UA) has been published to date. OBJECTIVE: We compared serum C-reactive protein (CRP), and interleukin-6(IL-6) between diabetic and non-diabetic patients with unstable angina (UA) to determine if difference in inflammatory activity is responsible for a worse prognosis in diabetic patients. We also evaluated the correlation between inflammatory markers and the metabolic profile in diabetic patients and the correlation between inflammatory response and in-hospital outcomes: death, acute myocardial infarction, congestive heart failure, and length of stay in hospital. METHODS: A prospective cohort study of 90 consecutive patients admitted to a chest pain unit with UA and divided into two groups, diabetic and non-diabetic. Serum CRP, IL-6, metabolic profile and leukocyte count were measured at hospital arrival. RESULTS: Forty-two patients (47%) were diabetic (age 62&#177;9) vs. 48 (53%) non-diabetic (age 63&#177;12). No differences between median C-reactive protein (1.78 vs. 2.23mg/l,p=0.74) and interleukin-6 (0 vs. 0pg/ml,p=0.31) were found between the two groups. There was a positive correlation between CRP and total cholesterol (rs = 0.21,p = 0.05), CRP and LDL-cholesterol (rs=0.22,p=0.04) and between CRP and leukocyte count (rs = 0.32, p = 0.02) in both groups. No associations were found between inflammatory markers and in-hospital outcomes. CONCLUSION: We found no difference in inflammatory activity between diabetic and non-diabetic patients with UA, suggesting that this clinical condition may result in balanced inflammatory activity between the two groups and increase acute-phase proteins independently of metabolic state.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Atherosclerosis</kwd>
        <kwd>diabetes mellitus</kwd>
        <kwd>inflammation</kwd>
        <kwd>angina pectoris</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p><undefined id="topo-body2"/>Comparison of inflammatory biomarkers between diabetic and non-diabetic patients with unstable angina</p>
      <p>
        <bold>Mar&#231;al de Oliveira Huoya<sup>I</sup>; Rafaela Andrade Penalva<sup>II</sup>; S&#237;lber Rodrigues Alves<sup>II</sup>; G&#237;lson Soares Feitosa<sup>I</sup>; Sandra Gadelha<sup>III</sup>; Ana Marice Teixeira Ladeia<sup>II,IV</sup></bold>
      </p>
      <p><sup>I</sup>Divis&#227;o de Cardiologia - Hospital Santa Izabel, Salvador - Brazil</p>
      <p><sup>II</sup>Funda&#231;&#227;o Baiana Para o Desenvolvimento das Ci&#234;ncias, Salvador - Brazil</p>
      <p><sup>III</sup>Funda&#231;&#227;o Osvaldo Cruz, Salvador - Brazil</p>
      <p><sup>IV</sup>Faculdade de Medicina da Universidade Federal da Bahia, Salvador - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Studies comparing inflammatory activity between diabetic and non-diabetic individuals with acute coronary syndrome are scarce, and none including only patients with unstable angina (UA) has been published to date.</p>
      <p><bold>OBJECTIVE:</bold> We compared serum C-reactive protein (CRP), and interleukin-6(IL-6) between diabetic and non-diabetic patients with unstable angina (UA) to determine if difference in inflammatory activity is responsible for a worse prognosis in diabetic patients. We also evaluated the correlation between inflammatory markers and the metabolic profile in diabetic patients and the correlation between inflammatory response and in-hospital outcomes: death, acute myocardial infarction, congestive heart failure, and length of stay in hospital.</p>
      <p><bold>METHODS:</bold> A prospective cohort study of 90 consecutive patients admitted to a chest pain unit with UA and divided into two groups, diabetic and non-diabetic. Serum CRP, IL-6, metabolic profile and leukocyte count were measured at hospital arrival.</p>
      <p><bold>RESULTS:</bold> Forty-two patients (47%) were diabetic (age 62&#177;9) vs. 48 (53%) non-diabetic (age 63&#177;12). No differences between median C-reactive protein (1.78 vs. 2.23mg/l,p=0.74) and interleukin-6 (0 vs. 0pg/ml,p=0.31) were found between the two groups. There was a positive correlation between CRP and total cholesterol (rs = 0.21,p = 0.05), CRP and LDL-cholesterol (rs=0.22,p=0.04) and between CRP and leukocyte count (rs = 0.32, p = 0.02) in both groups. No associations were found between inflammatory markers and in-hospital outcomes.</p>
      <p><bold>CONCLUSION:</bold> We found no difference in inflammatory activity between diabetic and non-diabetic patients with UA, suggesting that this clinical condition may result in balanced inflammatory activity between the two groups and increase acute-phase proteins independently of metabolic state. (Arq Bras Cardiol 2009;92(4):269-274)</p>
      <p><bold>Key words:</bold> Atherosclerosis / complications; diabetes mellitus; inflammation / complications; angina pectoris.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Atherosclerosis is responsible for 80% of all deaths in diabetic patients<sup>1</sup>. As the prevalence of diabetes is estimated to double by the year 2025, the burden of cardiovascular disease with this condition will dramatically increase<sup>2</sup>. </p>
      <p>Compared with non-diabetic individuals, diabetic patients have a two- to four-fold increased risk of coronary heart disease<sup>3</sup>, two fold-higher risk of short-term mortality after acute myocardial infarction<sup>4</sup>, and poorer results when submitted to angioplasty with increased risk of restenosis<sup>5</sup>. Inflammatory activity is increased in individuals with type 1<sup>6</sup> and type 2 diabetes and strongly associated with risk of atherothrombosis<sup>7</sup>. </p>
      <p>C-reactive protein (CRP) is the principal downstream mediator of acute phase response and is primarily derived via IL-6 dependent hepatic biosynthesis and has long been recognized as a very stable protein<sup>8</sup>. Levels of CRP increase very rapidly in response to trauma, inflammation, and infection and decrease just as rapidly with the resolution of the condition<sup>9</sup>. Thus, measurement of CRP is widely used to monitor various inflammatory states. The synthesis of CRP is predominantly under the control of IL-6<sup>10</sup>, which in turn has been assumed to originate from activated leukocytes, adipocytes, and endothelial cells<sup>11</sup>.</p>
      <p>Increased levels of C-reactive protein (CRP) and interleukin-6 (IL-6) are associated with higher incidence of adverse cardiac events in patients with acute coronary syndromes, as well as in patients undergoing coronary stenting<sup>12</sup>. Aggarwal et al<sup>13</sup> found increased CRP levels (two fold) in diabetic than in non-diabetic subjects with acute coronary syndrome before and after coronary stenting.</p>
      <p>Studies comparing inflammatory activity between diabetic and non-diabetic individuals with acute coronary syndrome are scarce, and none including only patients with unstable angina (UA) has been published to date. The aim of this study was to compare high sensitivity C-reactive protein (hs-CRP), interleukin-6 and leukocyte count levels between diabetic and non-diabetic patients to determine if differences in inflammatory activity could explain the worsened clinical or procedure results in diabetic patients with acute coronary syndrome.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Study design</bold>
      </p>
      <p>In this observational, cross-sectional study with a comparison group, performed at the chest pain unit of the Santa Izabel Hospital from February to October of 2005, 90 patients with unstable angina pectoris were consecutively included, irrespective of age and gender. Patients were classified into two groups: diabetic and non-diabetic subjects. At admission, all patients were immediately examined by a cardiologist who measured their heart rate, blood pressure and pulse oximetry. All patients received 200 mg of aspirin and underwent 12-lead electrocardiograms. Blood samples for laboratory evaluation were drawn within 15 minutes of admission.</p>
      <p> Inclusion criteria were age &gt; 30 years old, both sexes, unstable angina and time from onset of chest pain to admission not superior to 12 hours. </p>
      <p>Unstable angina was defined according to Braunwald<sup>14</sup>, and only patients with class IIIB were included in the study.</p>
      <p>Patients with recent myocardial infarction (less than four weeks), dilated cardiomyopathy or Chagas heart disease, atrial fibrillation, valvular heart disease, raised levels of myocardial necrosis markers within 12 hours of admission (troponin T &gt; 0.1 &#956;g/ml and creatine kinase-MB mass &gt; 4.94 &#956;g/ml with a characteristic rise and fall curve), thromboembolism, surgery, PTCA in the last four weeks, inflammatory or neoplastic disease, chronic renal failure and fever in the previous week were excluded. </p>
      <p>Patients were classified according to: age, sex, precordial pain at admission, TIMI risk score, diabetes duration, hypertension, smoking, previous coronary artery disease, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), previous myocardial infarction, dyslipidemia, chest pain duration, time from onset of chest pain to admission (delta T in minutes), alcohol intake, family history of premature coronary artery disease and body mass index calculated from self-reported height and weight. Previous treatment used before inclusion in this study and also in-hospital treatment according to the chest pain unit routine protocol were recorded. </p>
      <p>Diabetes was defined by occasional blood glucose <underline>&gt;</underline> 200 mg/dL or fasting glucose <underline>&gt;</underline> 126 mg/dl, use of oral hypoglycemic drugs or insulin treatment or self-reported history<sup>15</sup>. </p>
      <p>Dyslipidemia was defined by high lipid levels according to the Third National Cholesterol Education Program<sup>16</sup> or by use of lipid-lowering drugs. </p>
      <p> Death, acute myocardial infarction (AMI) characterized by troponin T levels <underline>&gt;</underline> 0.1 &#956;g/ml and ck-MB-mass levels <underline>&gt;</underline> 5.0 &#956;g/ml with a characteristic rise and fall curve, congestive heart failure (CHF) occurring before discharge and length of stay in hospital were considered as in-hospital outcomes.</p>
      <p> The local Bioethics Committee of our center approved the protocol study and all patients provided informed consent. </p>
      <p>
        <bold>Laboratory evaluation</bold>
      </p>
      <p>On admission, blood venous samples were obtained before intravenous administration of any drug (except for aspirin according to chest pain unit protocol), with a delay not superior to 15 minutes. Coded plasma samples were stored at -85&#186;C. CRP was measured via a high-sensitivity latex enhanced immunonephelometric assay on a BN II analyzer (Dade Bering, Newark, Del) at a Clinical Analyses Laboratory (LPC). The detection limit of C-reactive protein was 1.3 mg/l. The interassay coefficient of variation was 2.2%, and the intra-assay coefficient was 2.9%.</p>
      <p>Plasma concentration of IL-6 was measured by a commercially available enzyme-linked immunosorbent assay (Quantikine human IL-6, R&amp;D Systems, Minneapolis, MN) at Osvaldo Cruz Foundation (FioCruz). The lower detection limit of interleukin-6 was under 0.9 pg/ml. The interassay coefficient of variation was 6.4% and the intra-assay coefficient was 4.2%. </p>
      <p>Plasma glucose, triglyceride, total cholesterol, and HDL-cholesterol were determined using enzymatic colorimetric assays (reagents obtained from Boehringer Manhein Diagnostics, Mannheim, Germany). In subjects who had plasma triglyceride levels &lt; 400 mg/dl, LDL-cholesterol was calculated according to the Friedewald formula. When triglyceride levels were &gt; 400 mg/dl, LDL-cholesterol was measured by the enzymatic method on a Hitachi 902 automatic analyzer (Boehringer Mannheim, Mannheim, Germany). </p>
      <p>HbA<sub>1c</sub> levels were determined by a immunoturbidimetric immunoassay (Roche Diagnostics GmbH, D-68298 Manhein) with a normal range of 4.5-6, %. </p>
      <p>
        <bold>Statistical analyses </bold>
      </p>
      <p>The study was designed with 80% power to detect a two-fold C-reactive protein value difference between two groups. To obtain this difference, a mean value of 2.8 mg/L and a standard deviation of 4.48 mg/L were used<sup>17</sup>. Considering a type I error of 0.05, and a type II error of 0.20, 80 patients were required.</p>
      <p> C-reactive protein and IL-6 concentrations are presented as median and interquartile range. Baseline characteristics were compared by chi-square test or Fisher's exact test for categorical variables and Wilcoxon's rank-sum or Student's <italic>t</italic> test for continuous variables. Nonparametric tests were used to compare hs-CRP and IL-6 between groups (Mann-Whitney U test) and to determine correlations (Spearman's p test). All p values are 2-tailed, and values lower than 0.05 were considered statistically significant.</p>
      <p>SPSS statistical software (version 10.0, SPSS Inc., Chicago, Illinois, USA) was used for data analysis.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Baseline characteristics</bold>
      </p>
      <p>A total of 117 consecutive patients were admitted from February to October 2005 in a reference cardiologic tertiary hospital. We excluded 24 patients who had serum cardiac markers elevation within 12 hours after admission, as well as 1 patient with Chagas heart disease, 1 patient with chest pain after alcohol libation and 1 patient with chronic renal disease. Three out of the 24 patients had diabetes. Ninety subjects who fulfilled the inclusion criteria were studied. Mean age was 62 &#177;9 (range 34-87) years; 42 were diabetic and 48 non-diabetic. <xref ref-type="table" rid="tab1-body2">Table 1</xref> shows the baseline clinical and laboratory characteristics of non-diabetic and diabetic patients. There were no differences in baseline clinical characteristics between groups except for higher systolic blood pressure (158 &#177; 31 <italic>vs.</italic> 143 &#177; 31 mm/Hg, p = 0.02) and heart hate (75&#177;15 <italic>vs</italic>. 67&#177;12 beats/min, p=0.01) in diabetic patients at admission. The mean time from the onset of chest pain to admission in the chest pain unit was similar for diabetic and non-diabetic patients (4.3&#177; 0.6 <italic>vs.</italic> 4.0&#177; 0.5 h, p= 0.83). No differences were observed for previous treatment between diabetic and non-diabetic patients except for the use of hypoglycemic drugs and insulin.</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt01-en.jpg"/></table-wrap>
      <p>Time since last meal until blood samples were drawn was also similar between groups (4.9&#177; 3.1 <italic>vs.</italic> 5.0&#177;3.3 h, p=0.95). There were no differences in laboratory characteristics between groups except for higher admission plasma glucose (178&#177;78 <italic>vs.</italic> 105&#177;27 mg/dl, p&lt;0.001), fasting plasma glucose (130&#177;40 <italic>vs</italic> 96&#177;12 mg/dl, p&lt;0.001), and HbA1c (6.3&#177;4.2 <italic>vs</italic>. 3.4 &#177; 1.2 %, p &lt; 0.001).</p>
      <p>
        <bold>Inflammatory markers</bold>
      </p>
      <p> In the entire population, median hs-CRP, IL-6 and leukocyte count was respectively 2 mg/L (interquartile range 0.8 - 4.7 mg/L), 0 pg/ml (interquartile range 0 - 0 pg/ml) and 7900 l/mm<sup>3</sup> (interquartile range 6327- 9895 l/mm<sup>3</sup>).</p>
      <p>Median hs-CRP (1.78 mg/L <italic>vs</italic> 2.23 mg/L, p = 0.74), IL-6 concentrations (0 pg/mL <italic>vs,</italic> 0 pg/mL, p = 0.31) and the leukocyte count (8245 l/mm<sup>3</sup><italic>vs,</italic> 7520 l/mm<sup>3</sup>, p = 0.74) were similar in diabetic and non-diabetic subjects (<xref ref-type="table" rid="tab2-body2">Table 2</xref>).</p>
      <table-wrap id="tab2-body2">
        <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt02-en.jpg"/></table-wrap>
      <p>No difference was observed between groups when analyzed in accordance with three CRP ranges (&lt;1mg/L, 1 to 3mg/L and &gt;3mg/L): &lt; 1mg/L (16% <italic>vs,</italic> 14%, p=0.5), 1-3 mg/L (10% <italic>vs.</italic> 18%, p=0.32) and &gt; 3mg/L (14%<italic>vs</italic> 14%, p=0.7). The diabetic and non-diabetic groups had also similar distribution when analyzed in accordance with quartiles: &lt;0.8 mg/L (15% <italic>vs,</italic> 12%, p=0.36), 0.81-2.04 mg/L (12% <italic>vs.</italic> 13%, p=0.95), 2.05-4.7 mg/L (8% <italic>vs,</italic> 16%, p=0.12 and &gt;4.7 mg/L (14% <italic>vs.</italic> 13%, p=0.66).</p>
      <p>When IL-6 levels were analyzed as a categorical variable (0 pg/mL = no and &gt; 0 pg/mL = yes), positive results were similar in both groups, (17% <italic>vs.</italic> 8%, p=0.12).</p>
      <p>In the entire population, C-reactive protein levels were positively correlated with total cholesterol levels, (rs = 0.21 p=0.05), LDL cholesterol levels (rs = 0.22, p=0.04) and leukocytes count (rs = 0.32, p = 0.02).</p>
      <p>
        <bold>In-hospital outcomes</bold>
      </p>
      <p>The overall mean hospital stay was 12 days, with a median of 7 days (range 2-125 days).</p>
      <p>During the in-hospital period there were no differences between diabetic and non-diabetic subjects with respect to occurrence of congestive heart failure (5% <italic>vs.</italic> 0%, p=0.21), acute myocardial infarction (5% <italic>vs.</italic> 2%, p=0.60), death (25 <italic>vs.</italic> 0%, p=0.47) and median hospital stay (8 days <italic>vs.</italic> 7 days, p=0.44). When combined outcomes were analyzed, events were also similar in both groups (12% <italic>vs</italic>. 2%, p=0.06, RR=5.7; 95% CI 0.7 to 56) (<xref ref-type="table" rid="tab3-body2">Table 3</xref>).</p>
      <table-wrap id="tab3-body2">
        <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt03-en.jpg"/></table-wrap>
      <p>When subjects who had in-hospital events were compared with those without events, median hs-CRP was similar in both groups for CHF (8.1mg/L <italic>vs</italic> 2.4 mg/L, p=0.47), AMI (7.8mg/L <italic>vs</italic> 1.7 mg/L, p=0.81) and cardiovascular death (5.66 mg/L <italic>vs</italic> 2.04 mg/L, p=0.41). No difference was likewise observed for respectively median IL-6 and leukocyte count to CHF (0 pg/mL <italic>vs</italic> 0 pg/mL, p = 0.58; 9590 l/mm<sup>3</sup><italic>vs</italic> 7460 l/mm<sup>3</sup>, p = 0.53), AMI (0 pg/mL <italic>vs</italic> 0 pg/mL, p = 0.58; 7925 l/mm<sup>3</sup><italic>vs</italic> 7860 l/mm<sup>3</sup>, p = 0.5) and death (0 pg/mL <italic>vs</italic> 0 pg/mL, p = 0.70; 11500 l/mm<sup>3</sup><italic>vs</italic> 7900 l/mm<sup>3</sup>, p = 0.22).</p>
      <p>There was no correlation between length of stay in hospital and hs-CRP levels (rs=0.02, p=0.86), IL-6 (rs=0.09, p=0.44) or leukocyte count (rs=0.21, p=0.85).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>There are few clinical studies comparing inflammation markers between diabetic and non-diabetic subjects with acute coronary syndrome, especially involving exclusively patients with unstable angina. </p>
      <p>Moreno et al<sup>18</sup> found that, in diabetic patients, coronary tissue exhibits a larger content of lipid-rich atheroma, macrophage infiltration, and subsequent thrombosis than tissue from patients without diabetes, suggesting that there is an increased vulnerability for plaque disruption and thrombosis in patients with diabetes mellitus. The same author reviewed the pathogenesis of diabetes atherosclerosis<sup>19</sup> and supported the idea that patients with diabetes mellitus have more inflammatory activity than the general population with atherosclerosis.</p>
      <p>However, in this study no differences were observed in hs-CRP and IL-6 concentrations between diabetic and non-diabetic patients with unstable angina.</p>
      <p> Aggarwal et al<sup>13</sup>, evaluating inflammatory activity measuring hs-CRP levels in 75 patients with acute coronary syndrome before, during and after coronary stenting in diabetic and non-diabetic individuals, concluded that diabetic patients with acute coronary syndrome had increased inflammatory activity before the procedure but after 24 hours there were no differences between diabetic and non-diabetic patients. Nevertheless the authors in their methodology did not describe fundamental information to conclude that in fact they had studied a population with acute coronary syndrome. Data on the time from onset of chest pain to admission or even the stenting procedure (first blood sample) was not informed. Moreover the author included patients with stable angina and non-ST elevation acute myocardial infarction when the necrosis factor could act as a confounding variable<sup>20</sup> and differently from our study, which used validated criteria to define diabetes, the authors did not even describe glucose levels.</p>
      <p> Analyzing the CRP levels between the two groups, we observed before stenting procedure that diabetic patients had two-fold inflammatory activity than non-diabetic patients but after coronary stenting (endothelial aggression) there were no differences in hs-CRP concentrations between the two groups. Gottsauner et al<sup>21</sup> found that the persistence of elevated C-reactive protein plasma levels 96 h after stent implantation might reflect a prolonged inflammatory reaction to coronary stent implantation.</p>
      <p>The role of acute endothelial aggression as a stimulus to an intense inflammatory response could be also present in unstable angina and would justify our findings and enhance the significance of our results. </p>
      <p>It is interesting to note that in our study, we used a very careful methodology to include UA patients. All subjects were rigorously labeled by validated criteria as unstable angina to avoid interference of the necrosis factor as a confounding variable. Were admitted in a reference emergence unit to cardiologic patients which the pos-test probability is higher than 80% to patients with typical chest pain and age equal or superior to 60 years. Moreover, at the end of the study 94% of the patients had the atherosclerotic disease confirmed by coronary angiography. Lastly, the homogeneity between groups was demonstrated by the lack of statistically significant differences in baseline characteristics.</p>
      <p>Our findings with statistically significant differences (SBP and HR) may be explained by the trend towards more severe chest pain at admission in the diabetic group, contrary to the original concept<sup>22</sup> that is currently being highly questioned<sup>23</sup>.</p>
      <p>Contrary to our study, Sanchez et al<sup>24</sup> observed that diabetic patients with non-ST elevation acute coronary syndrome showed higher inflammatory activity than non- diabetic ones. Nevertheless, diabetic patients had a higher leukocyte count than non-diabetic subjects, and the authors included no instrument in their methodology to detect silent infectious process, especially in diabetic women<sup>25</sup>. In our study, we conducted urinalysis in all the patients and explored the upper airways, including the auditory canal, to exclude silent infections. Moreover, there were no differences in leukocyte count measured at admission between diabetic and non-diabetic patients, suggesting no differences in previous inflammatory condition due to systemic infectious process.</p>
      <p>Moreover, Sanchez did not describe admission and fasting blood glucose and lipid profile. It is important to underscore that the metabolic state of diabetes is characterized by hyperglycemia and dyslipidemia and is associated to endothelial lesion and consequently to increased inflammation markers<sup>19,26,27</sup>. </p>
      <p>Regarding the positive correlation between hs-CRP concentrations and leukocyte count, Danesh et al<sup>28</sup> described a strong association between leukocyte count and coronary artery disease development and Stewart et al<sup>29</sup> observed higher mortality reduction associated to the use of pravastatin in those patients who showed increased leukocyte count values at admission.</p>
      <p>In this study, upon analyzing all included patients with unstable angina, a weak correlation was observed between hs-CRP and total and LDL cholesterol, but superior to that found in previous studies<sup>30,31 </sup>that did not include patients with acute coronary syndrome.</p>
      <p>In our study, we did not observe higher in-hospital outcomes between diabetic and non-diabetic patients despite literature findings<sup>32</sup>, probably because of the reduced follow-up period (median 8 days) and few patients included (small sample), to find more in-hospital outcomes such as CHF, AMI and death (reduced power) in patients with unstable angina. </p>
      <p>Another limitation was the fact that the mean time from onset of chest pain to admission in the emergency room (4 h) until collection of blood samples to measure hs-CRP may have been insufficient to find the inflammatory process in course. However, this occurrence would not explain the similar hs-CRP results between two groups. </p>
      <p>Our findings suggest that events involved in an acute coronary screening, such as unstable angina, propitiate an important, yet similar, inflammatory response between diabetic and non-diabetic patients, suggesting that inflammation response resulting from an acute coronary syndrome is more intense and acute than the inflammation response resulting from diabetes where the process is more continuous and slower and endothelial aggression is lasting. Another possibility is that the use of statin (in our study similar in both diabetic and non-diabetic patients) may be more effective in diabetic patients, since more intense anti-inflammatory effect was described in individuals with enhanced inflammatory activity<sup>29</sup>. It is important to underscore that our diabetic patients were well controlled (mean Hba1c=6.3%) and this finding may have decreased hyperglycemia impact on endothelial aggression.</p>
      <p>Regarding everything we discussed in our study, some questions must be answered: Are the inflammation characteristics observed in diabetes different from those in acute coronary syndrome? Is there any way to evaluate this? Is the statin effect higher among diabetic than among non-diabetic patients? Could this superior effect explain the equality of inflammation activity between groups when they were admitted in the study with acute coronary syndrome? Is the inflammatory response in an acute coronary syndrome so intense that it could equilibrate inflammation activity between diabetic and non-diabetic patients? </p>
      <p>Our findings allow us to conclude in this group of patients that inflammation activity is similar between diabetic and non-diabetic patients with unstable angina and in these patients hs-CRP showed a positive correlation with total and LDL cholesterol as well as with leukocyte count. These findings also underscore the importance of CRP as an endothelial aggression marker in acute coronary syndrome, as well as of the multifactorial aspect of the atherothrombosis process. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by Funda&#231;&#227;o de Amparo a Pesquisa do estado da Bahia (FAPESB).</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of master submitted by Mar&#231;al de Oliveira Huoya, from Escola Bahiana de Medicina e Sa&#250;de P&#250;blica</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Comparaci&#243;n de biomarcadores inflamatorios entre pacientes diab&#233;ticos y no-diab&#233;ticos con angina inestable</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: Pocos estudios compararon la actividad inflamatoria entre pacientes diab&#233;ticos y no-diab&#233;ticos con s&#237;ndrome coronario agudo, y todav&#237;a no se public&#243; ninguno que investigara solamente a los portadores de angina inestable (AI). OBJETIVO: Este estudio tuvo dos objetivos. En primer lugar, comparar los niveles s&#233;ricos de prote&#237;na C reactiva (PCR) y interleuquina-6 (IL-6) en pacientes diab&#233;ticos y no-diab&#233;ticos con angina inestable (AI) para determinar si la diferencia en la actividad inflamatoria justifica el empeoramiento pron&#243;stico en los pacientes diab&#233;ticos. En segundo, evaluar la correlaci&#243;n entre los marcadores inflamatorios y el perfil metab&#243;lico en pacientes diab&#233;ticos y entre la respuesta inflamatoria y los desenlaces hospitalarios, como muerte, infarto agudo de miocardio, insuficiencia cardiaca congestiva y tiempo de hospitalizaci&#243;n. M&#201;TODOS: Estudio de cohorte prospectiva de 90 pacientes consecutivos, ingresados a la Unidad de Dolor Tor&#225;cico con angina inestable. Se dividieron a los pacientes en dos grupos: diab&#233;ticos y no-diab&#233;ticos. Los niveles s&#233;ricos de PCR e IL-6, el perfil metab&#243;lico y el conteo de leucocitos se obtuvieron al ingreso al hospital. RESULTADOS: De todos los pacientes analizados, 42 (47%) eran diab&#233;ticos (edad 62 &#177; 9) y 48 (53%) no eran diab&#233;ticos (edad 63 &#177; 12). No se encontraron diferencias entre la mediana de la PCR (1,78 vs. 2,23 mg/l, p = 0,74) y de la IL-6 (0 vs. 0 pg/ml, p = 0,31) entre los dos grupos. Hubo una correlaci&#243;n positiva entre la PCR y el colesterol total (rs = 0, 21, p = 0, 05), la PCR y el colesterol LDL (rs = 0,22, p = 0,04) y la PCR y el conteo de leucocitos (rs = 0,32, p = 0,02) en los dos grupos. No se encontr&#243; ninguna asociaci&#243;n entre los marcadores inflamatorios y los desenlaces hospitalarios. CONCLUSI&#211;N: No encontramos diferencia en la actividad inflamatoria entre los pacientes diab&#233;ticos y no-diab&#233;ticos con AI, lo que indica que ese cuadro cl&#237;nico puede equilibrar la actividad inflamatoria entre los dos grupos y aumentar la concentraci&#243;n de marcadores inflamatorios de fase aguda, independientemente del estado metab&#243;lico.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Aterosclerosis</kwd>
        <kwd>diabetes mellitus</kwd>
        <kwd>inflamaci&#243;n</kwd>
        <kwd>angina pectoris</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="add1-body3"/>Comparaci&#243;n de biomarcadores inflamatorios entre pacientes diab&#233;ticos y no-diab&#233;ticos con angina inestable</p>
      <p>
        <bold>Mar&#231;al de Oliveira Huoya<sup>I</sup>; Rafaela Andrade Penalva<sup>II</sup>; S&#237;lber Rodrigues Alves<sup>II</sup>; G&#237;lson Soares Feitosa<sup>I</sup>; Sandra Gadelha<sup>III</sup>; Ana Marice Teixeira Ladeia<sup>II,IV</sup></bold>
      </p>
      <p><sup>I</sup>Divis&#227;o de Cardiologia - Hospital Santa Izabel, Salvador - Brasil</p>
      <p><sup>II</sup>Funda&#231;&#227;o Baiana Para o Desenvolvimento das Ci&#234;ncias, Salvador - Brasil</p>
      <p><sup>III</sup>Funda&#231;&#227;o Osvaldo Cruz, Salvador - Brasil</p>
      <p><sup>IV</sup>Faculdade de Medicina da Universidade Federal da Bahia, Salvador - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> Pocos estudios compararon la actividad inflamatoria entre pacientes diab&#233;ticos y no-diab&#233;ticos con s&#237;ndrome coronario agudo, y todav&#237;a no se public&#243; ninguno que investigara solamente a los portadores de angina inestable (AI).</p>
      <p><bold>OBJETIVO:</bold> Este estudio tuvo dos objetivos. En primer lugar, comparar los niveles s&#233;ricos de prote&#237;na C reactiva (PCR) y interleuquina-6 (IL-6) en pacientes diab&#233;ticos y no-diab&#233;ticos con angina inestable (AI) para determinar si la diferencia en la actividad inflamatoria justifica el empeoramiento pron&#243;stico en los pacientes diab&#233;ticos. En segundo, evaluar la correlaci&#243;n entre los marcadores inflamatorios y el perfil metab&#243;lico en pacientes diab&#233;ticos y entre la respuesta inflamatoria y los desenlaces hospitalarios, como muerte, infarto agudo de miocardio, insuficiencia cardiaca congestiva y tiempo de hospitalizaci&#243;n.</p>
      <p><bold>M&#201;TODOS:</bold> Estudio de cohorte prospectiva de 90 pacientes consecutivos, ingresados a la Unidad de Dolor Tor&#225;cico con angina inestable. Se dividieron a los pacientes en dos grupos: diab&#233;ticos y no-diab&#233;ticos. Los niveles s&#233;ricos de PCR e IL-6, el perfil metab&#243;lico y el conteo de leucocitos se obtuvieron al ingreso al hospital.</p>
      <p><bold>RESULTADOS:</bold> De todos los pacientes analizados, 42 (47%) eran diab&#233;ticos (edad 62 &#177; 9) y 48 (53%) no eran diab&#233;ticos (edad 63 &#177; 12). No se encontraron diferencias entre la mediana de la PCR (1,78 vs. 2,23 mg/l, p = 0,74) y de la IL-6 (0 vs. 0 pg/ml, p = 0,31) entre los dos grupos. Hubo una correlaci&#243;n positiva entre la PCR y el colesterol total (rs = 0, 21, p = 0, 05), la PCR y el colesterol LDL (rs = 0,22, p = 0,04) y la PCR y el conteo de leucocitos (rs = 0,32, p = 0,02) en los dos grupos. No se encontr&#243; ninguna asociaci&#243;n entre los marcadores inflamatorios y los desenlaces hospitalarios.</p>
      <p><bold>CONCLUSI&#211;N:</bold> No encontramos diferencia en la actividad inflamatoria entre los pacientes diab&#233;ticos y no-diab&#233;ticos con AI, lo que indica que ese cuadro cl&#237;nico puede equilibrar la actividad inflamatoria entre los dos grupos y aumentar la concentraci&#243;n de marcadores inflamatorios de fase aguda, independientemente del estado metab&#243;lico. (Arq Bras Cardiol 2009;92(4):276-282)</p>
      <p><bold>Palabras clave:</bold> Aterosclerosis / complicaciones, diabetes mellitus, inflamaci&#243;n / complicaciones, angina pectoris / angina de pecho.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La aterosclerosis es la responsable del 80% de todas las muertes en pacientes diab&#233;ticos<sup>1</sup>. Como las estimaciones revelan que la prevalencia de diabetes se duplicar&#225; hasta el a&#241;o 2025, la incidencia de enfermedad cardiovascular asociada a diabetes aumentar&#225; substancialmente<sup>2</sup>.</p>
      <p>Comparados a los individuos no-diab&#233;ticos, los pacientes diab&#233;ticos tienen un riesgo de dos a cuatro veces mayor de desarrollar enfermedad coronaria<sup>3</sup>; un riesgo dos veces mayor de mortalidad, en un corto plazo tras infarto agudo de mioc&#225;rdio<sup>4,5</sup> y resultados peores cuando sometidos a la angioplastia, con mayor riesgo de reestenosis. La actividad inflamatoria es elevada en los pacientes con diabetes tipo 1<sup>6</sup> y tipo 2, adem&#225;s de estar fuertemente asociada al riesgo de aterotrombosis<sup>7</sup>.</p>
      <p>La prote&#237;na C reactiva (PCR) es el principal mediador de la respuesta de la fase aguda. Desde hace mucho tiempo, se considera bastante estable<sup>8 </sup>esa prote&#237;na, derivada principalmente de la bios&#237;ntesis hep&#225;tica dependiente de la IL-6. Los niveles de PCR aumentan r&#225;pidamente en reacci&#243;n a trauma, inflamaci&#243;n e infecci&#243;n. Cuando del desaparecimiento de esos problemas, los mismos niveles se reducen<sup>9</sup>. Por ese motivo, la dosificaci&#243;n de PCR es com&#250;nmente usada para el monitoreo de varios estados inflamatorios. La s&#237;ntesis de PCR es controlada principalmente por la IL-6<sup>10</sup>, que, a su vez, es secretada por leucocitos activados, adipocitos y c&#233;lulas endoteliais<sup>11</sup>.</p>
      <p>El aumento en los niveles de prote&#237;na C reactiva (PCR) e interleuquina- 6 (IL-6) est&#225; asociado a una mayor incidencia de eventos cardiacos adversos en pacientes con s&#237;ndromes coronarios agudos, as&#237; como en pacientes sometidos a implante de <italic>stent </italic>coronario<sup>12</sup>. Aggarwal et al. <sup>13</sup> constataron que los niveles de PCR eran m&#225;s elevados (el doble) en portadores de s&#237;ndrome coronario agudo diab&#233;ticos que en los no-diab&#233;ticos, antes y luego de la colocaci&#243;n del <italic>stent </italic>coronario.</p>
      <p>Pocos estudios publicados hasta hoy han comparado la actividad inflamatoria entre portadores de s&#237;ndrome coronario agudo diab&#233;ticos y no-diab&#233;ticos, y ning&#250;n de ellos incluy&#243; s&#243;lo a pacientes con angina inestable. Este estudio tiene por objeto comparar los niveles de prote&#237;na C reactiva ultrasensible (PCR-us), IL-6 y el conteo de leucocitos entre los pacientes diab&#233;ticos y no-diab&#233;ticos para determinar si la existencia de diferencias en la actividad inflamatoria puede explicar la peor evoluci&#243;n cl&#237;nica o los resultados de procedimientos en pacientes diab&#233;ticos con s&#237;ndrome coronario agudo. </p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Dise&#241;o del estudio</bold>
      </p>
      <p>Este estudio observacional y de corte transversal, con comparaci&#243;n entre grupos, se realiz&#243; en la Unidad de Dolor Tor&#225;cico del Hospital Santa Isabel, entre febrero y octubre de 2005. El estudio incluy&#243; a 90 pacientes consecutivos con angina inestable, independientemente de edad o sexo, que se clasificaron en dos grupos: diab&#233;ticos y no-diab&#233;ticos. Al ingreso, todos los pacientes fueron examinados inmediatamente por un cardi&#243;logo, que midi&#243; la frecuencia cardiaca, la presi&#243;n arterial y la oximetr&#237;a de pulso. Todos los individuos recibieron 200 mg de aspirina y fueron sometidos a un electrocardiograma de 12 derivaciones. Adem&#225;s de ello, se colectaron muestras de sangre para an&#225;lisis laboratorial en la atenci&#243;n de emergencia, con un retardo m&#225;ximo de 15 minutos.</p>
      <p>Los criterios de inclusi&#243;n en el estudio fueron: edad superior a 30 a&#241;os, individuos de ambos sexos, angina inestable y tiempo entre el inicio del dolor tor&#225;cico e internaci&#243;n de un m&#225;ximo de 12 horas. </p>
      <p>La angina inestable se defini&#243; de acuerdo con la clasificaci&#243;n de Braunwald<sup>14</sup>, y se incluyeron en el estudio solamente a los pacientes con clase IIIB. </p>
      <p>Se excluyeron a los pacientes con infarto de miocardio reciente (menos de cuatro semanas); cardiomiopat&#237;a dilatada o chag&#225;sica; fibrilaci&#243;n atrial; valvulopat&#237;a; niveles s&#233;ricos elevados de marcadores de necrosis mioc&#225;rdica hasta 12 horas tras la internaci&#243;n (troponina T &gt; 0,1 &#181;g/ml y fracci&#243;n MB de la creatinofosfokinasa &gt; 4,94 &#181;g/ml con curva caracter&#237;stica de elevaci&#243;n y descenso); tromboembolia; cirug&#237;a; angioplastia coronaria transluminal percut&#225;nea (ACTP) en las cuatro semanas anteriores; enfermedad inflamatoria o neopl&#225;sica; insuficiencia renal cr&#243;nica y fiebre en la &#250;ltima semana.</p>
      <p>A los pacientes se les clasificaron de acuerdo con los factores que siguen a continuaci&#243;n: edad; sexo; dolor precordial al momento de la internaci&#243;n; score de riesgo TIMI; duraci&#243;n de diabetes; hipertensi&#243;n; tabaquismo; enfermedad arterial coronaria previa; angioplastia coronaria transluminal percut&#225;nea (ACTP); cirug&#237;a de revascularizaci&#243;n mioc&#225;rdica (CRM); infarto de miocardio previo; dislipidemia; duraci&#243;n del dolor tor&#225;cico; tiempo transcurrido entre el inicio del dolor tor&#225;cico y la internaci&#243;n (delta T en minutos); consumo de alcohol; historia familiar de enfermedad arterial coronaria precoz e &#237;ndice de masa corporal calculado por medio del valor de peso y altura declarados por los pacientes. Todav&#237;a se registraron el tratamiento realizado antes de la inclusi&#243;n en el estudio y el tratamiento hospitalario, realizado de conformidad al protocolo de rutina de la Unidad de Dolor Tor&#225;cico.</p>
      <p>Se defini&#243; la diabetes por glicemia ocasional <underline>&gt;</underline> 200 mg/dL &#243; glicemia en ayuno <underline>&gt;</underline> 126mg/dL, la utilizaci&#243;n de hipoglucemiantes orales o insulina, o historia relatada por el paciente<sup>15</sup>. </p>
      <p>Se defini&#243; la dislipidemia por niveles lip&#237;dicos elevados, de acuerdo con el<italic> III National Cholesterol Education Program</italic><sup>16</sup> o por la utilizaci&#243;n de f&#225;rmacos hipolipemiantes.</p>
      <p>Se consideraron como desenlaces hospitalarios muerte; infarto agudo de miocardio (IAM), caracterizado por niveles de troponina-T <underline>&gt;</underline> 0,1 &#181;g/ml y de CK-MB masa <underline>&gt;</underline> 5,0&#181;g/ml con curva caracter&#237;stica de elevaci&#243;n y descenso; insuficiencia cardiaca congestiva (ICC) antes del alta y tiempo de internaci&#243;n. </p>
      <p>El Comit&#233; de Bio&#233;tica local de nuestro centro aprob&#243; el protocolo del estudio, y todos los pacientes firmaron un formulario de consentimiento informado.</p>
      <p>
        <bold>Evaluaci&#243;n laboratorial</bold>
      </p>
      <p>A la internaci&#243;n, se colectaron muestras de sangre venosa antes de la administraci&#243;n intravenosa de cualquier f&#225;rmaco (a excepci&#243;n de aspirina, de conformidad al protocolo de la Unidad de Dolor Tor&#225;cico), con una demora de un m&#225;ximo de 15 minutos. Muestras de plasma identificadas se almacenaron a -85 &#186;C. La PCR se dosific&#243; por medio de ensayo de inmunonefelometr&#237;a hipersensible con part&#237;culas de l&#225;tex, en un analizador BN II (<italic>Dade Bering</italic>, Newark, Del), en el Laboratorio de An&#225;lisis Cl&#237;nicos. El l&#237;mite inferior de detecci&#243;n de la prote&#237;na C reactiva fue 1,3mg/l. El coeficiente de variaci&#243;n entre ensayos fue de un 2,2%, y el coeficiente intraensayo, de un 2,9%. </p>
      <p>La concentraci&#243;n plasm&#225;tica de IL-6 se determin&#243; por medio de ensayo inmunoenzim&#225;tico (<italic>Quantikine human </italic>IL-6, <italic>R&amp;D Systems, Minneapolis</italic>, MN) en la Fundaci&#243;n Osvaldo Cruz (FioCruz). El l&#237;mite inferior de detecci&#243;n de la interleuquina-6 fue menos de 0,9 pg/ml. El coeficiente de variaci&#243;n entre ensayos fue de un 6,4%, y el coeficiente intraensayo, de un 4,2%.</p>
      <p>Los niveles plasm&#225;ticos de glucosa, triglic&#233;ridos, colesterol total y colesterol HDL se determinaron por medio de ensayos enzim&#225;ticos calorim&#233;tricos (reactivos de <italic>Boehringer Mannheim Diagnostics</italic>, Mannheim, Alemania). En los individuos con niveles plasm&#225;ticos de triglic&#233;ridos inferiores a<italic> 400 mg/dl, el colesterol LDL se calculaba de acuerdo con la f&#243;rmula de Friedewald. Cuando los niveles de </italic>triglic&#233;ridos <italic>estaban superiores a 400 mg/dl, se dosificaba el colesterol LDL con el m&#233;todo enzim&#225;tico en un analizador autom&#225;tico Hitachi 902 (Boehringer Mannheim</italic>, Mannheim, Alemania).</p>
      <p>Se determinaron los niveles de HbA<sub>1c </sub>mediante inmunoensayo inmunoturbidim&#233;trico (<italic>Roche Diagnostics GmbH</italic>, D-68298, Mannheim), con valores normales entre un 4,5% y un 6,1 %. </p>
      <p>
        <bold>An&#225;lisis estad&#237;sticos</bold>
      </p>
      <p>El estudio se dise&#241;&#243; para que tuviera un poder estad&#237;stico del 80% en la detecci&#243;n de una diferencia dos veces mayor en el valor de la prote&#237;na C reactiva entre los dos grupos. Para que se obtuviera esa diferencia se utilizaron un valor promedio de 2,8 mg/L y una desviaci&#243;n est&#225;ndar de 4,48 mg/L<sup>17</sup>. Tom&#225;ndose en consideraci&#243;n un error tipo I de 0,05 y otro tipo II de 0,20, fueron necesarios 80 pacientes.</p>
      <p>Las concentraciones de prote&#237;na C reactiva e IL-6 se presentaron como mediana e intervalo intercuart&#237;lico. Se compararon las caracter&#237;sticas basales con la prueba Chi-cuadrado o el test exacto de Fisher, para variables categ&#243;ricas; y la prueba de Wilcoxon o la prueba <italic>t</italic> de Student, para variables continuas. Se utilizaron pruebas no param&#233;tricas para comparar la PCR-us y la IL-6 entre los grupos (test U de Mann-Whitney) y determinar correlaciones (test<italic> p</italic> de Spearman). Todos los valores de <italic>p</italic> son de dos colas, y se consideraron estad&#237;sticamente significantes los valores inferiores a 0,05.</p>
      <p>Se analizaron los datos con la ayuda del software estad&#237;stico SPSS (versi&#243;n 10.0, SPSS Inc., Chicago, Illinois, EUA).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Caracter&#237;sticas iniciales</bold>
      </p>
      <p>De febrero a octubre del 2005, se internaron a 117 pacientes consecutivos en un hospital cardiol&#243;gico de nivel terciario. Se excluyeron a 24 pacientes que presentaron elevaci&#243;n de los marcadores s&#233;ricos cardiacos hasta 12 horas luego de la internaci&#243;n; un paciente con cardiomiopat&#237;a chag&#225;sica; un paciente con dolor tor&#225;cico tras ingesti&#243;n de bebida alcoh&#243;lica; un paciente con enfermedad renal cr&#243;nica. Tres de los 24 pacientes excluidos eran diab&#233;ticos. Se estudi&#243; al total de 90 individuos que respondieron a los criterios de inclusi&#243;n. El promedio de edad de los pacientes era 62 &#177; 9 (34 a 87 a&#241;os), 42 eran diab&#233;ticos y 48 no eran diab&#233;ticos. </p>
      <p>La <xref ref-type="table" rid="tab01-body3">Tabla 1</xref> detalla las caracter&#237;sticas cl&#237;nicas y laboratoriales iniciales de los pacientes diab&#233;ticos y no-diab&#233;ticos. No hubo diferencias en las caracter&#237;sticas cl&#237;nicas iniciales entre los dos grupos, excepto por mayor presi&#243;n arterial sist&#243;lica (158 &#177; 31 <italic>vs.</italic> 143 &#177; 31 mm Hg, p = 0,02) y frecuencia cardiaca (75 &#177; 15 vs. 67 &#177; 12 latidos/minuto, <italic>p</italic> = 0,01) en los pacientes diab&#233;ticos a la internaci&#243;n. El tiempo promedio transcurrido entre el inicio del dolor tor&#225;cico y la internaci&#243;n en la Unidad de Dolor Tor&#225;cico fue semejante para los pacientes diab&#233;ticos y no-diab&#233;ticos (4,3 &#177; 0,6 <italic>vs.</italic> 4,0 &#177; 5,0h, <italic>p</italic> = 0,83). No se observaron diferencias en relaci&#243;n con el tratamiento previo entre pacientes diab&#233;ticos y no-diab&#233;ticos, excepto por la utilizaci&#243;n de f&#225;rmacos hipoglucemiantes e insulina. </p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt01-es.jpg"/></table-wrap>
      <p>El tiempo transcurrido entre la &#250;ltima comidan y la colecta de muestras de sangre tambi&#233;n fue semejante en los dos grupos (4,9 &#177; 3,1 <italic>vs.</italic> 5,0 &#177; 3,3h, <italic>p</italic> = 0,95). No hubo diferencias en las caracter&#237;sticas laboratoriales entre los dos grupos, a excepci&#243;n de los niveles m&#225;s elevados de glucemia a la internaci&#243;n (178 &#177; 78 <italic>vs.</italic> 105 &#177; 27mg/dl, <italic>p</italic> &lt; 0,001), de glucemia en ayuno (130 &#177; 40 <italic>vs.</italic> 96 &#177;12 mg/dl, <italic>p </italic>&lt; 0,001) y de HbA<sub>1c</sub> (6,3 &#177; 4,2 <italic>vs. </italic>3,4 &#177; 1,2 %, <italic>p</italic> &lt; 0,001).</p>
      <p>
        <bold>Marcadores inflamatorios</bold>
      </p>
      <p>Al considerarse el total de la poblaci&#243;n del estudio, la mediana de la PCR-us, de la IL-6 y del conteo de leucocitos fue, respectivamente, 2 mg/L (intervalo intercuart&#237;lico 0,8 - 4,7 mg/L), 0 pg/ml (intervalo intercuart&#237;lico 0 - 0 pg/ml) y 7.900/mm<sup>3</sup> (intervalo intercuart&#237;lico 6327 - 9895 l/mm<sup>3</sup>).</p>
      <p>La mediana de las concentraciones de PCR-us (1,78 mg/L <italic>vs.</italic> 2,23 mg/l, <italic>p</italic> = 0,74) y de la IL-6 (0 <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,31) y del conteo de leucocitos (8.245/mm<sup>3</sup><italic>vs.</italic> 7520/mm<sup>3</sup>, p = 0,74) fueron semejantes entre los individuos diab&#233;ticos y no-diab&#233;ticos (<xref ref-type="table" rid="tab02-body3">Tabla 2</xref>).</p>
      <table-wrap id="tab02-body3">
        <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt02-es.jpg"/></table-wrap>
      <p>No se observ&#243; ninguna diferencia entre los grupos cuando se les analizaron de acuerdo con tres franjas de PCR (&lt; 1 mg/L, 1 a 3 mg/L y &gt; 3 mg/L): &lt; 1 mg/L (16% <italic>vs.</italic> 14%, <italic>p</italic> = 0,5), 1 a 3 mg/L (10% <italic>vs.</italic> 18%, <italic>p</italic> = 0,32) y &gt; 3 mg/L (14% <italic>vs. </italic>14%, <italic>p</italic> = 0,7). Los grupos de pacientes diab&#233;ticos y no-diab&#233;ticos tambi&#233;n tuvieron distribuci&#243;n semejante cuando analizados con relaci&#243;n a los cuartiles: &lt; 0,8 mg/L (15% <italic>vs.</italic> 12%, <italic>p</italic> = 0,36), 0,81 a 2,04 mg/L (12% <italic>vs. </italic>13%, <italic>p</italic> = 0,95), 2,05 a 4,7 mg/L (8% <italic>vs.</italic> 16%, <italic>p</italic> = 0,12) y &gt; 4,7 mg/L (14% <italic>vs.</italic> 13%, <italic>p</italic> = 0,66).</p>
      <p>Cuando se analizaron los niveles de IL-6 como variables categ&#243;ricas (0 pg/mL = no y &gt; 0 pg/mL = s&#237;), los resultados positivos fueron semejantes en los dos grupos (17% <italic>vs.</italic> 8%, <italic>p</italic> = 0,12).</p>
      <p>En toda poblaci&#243;n del estudio, los niveles de prote&#237;na C reactiva fueron positivamente correlacionados con los niveles de colesterol total (r<sub>s</sub> = 0,21,<italic> p</italic> = 0,05), los niveles de colesterol LDL (r<sub>s</sub> = 0,22, <italic>p</italic> = 0,04) y el conteo de leucocitos (r<sub>s</sub> = 0,32, <italic>p</italic> = 0,02).</p>
      <p>
        <bold>Desenlaces hospitalarios</bold>
      </p>
      <p>El promedio del tiempo de hospitalizaci&#243;n fue de 12 d&#237;as, con mediana de 7 d&#237;as (2 a 125 d&#237;as).</p>
      <p>Durante el per&#237;odo de internaci&#243;n, no hubo diferencias entre los pacientes diab&#233;ticos y no-diab&#233;ticos con relaci&#243;n a la ocurrencia de insuficiencia cardiaca congestiva (5%<italic> vs.</italic> 0%, <italic>p</italic> = 0,21), infarto agudo de miocardio (5% <italic>vs.</italic> 2%, <italic>p</italic> = 0,60), muerte (25 <italic>vs.</italic> 0%, <italic>p</italic> = 0,47) y mediana del tiempo de hospitalizaci&#243;n (8 d&#237;as <italic>vs.</italic> 7 d&#237;as, <italic>p</italic> = 0,44). Los desenlaces combinados tambi&#233;n se mostraron semejantes en los dos grupos (12% <italic>vs. </italic>2%, <italic>p</italic> = 0,06, RR = 5,7; IC 95%, 0,7 a 56) (<xref ref-type="table" rid="tab03-body3">Tabla 3</xref>). </p>
      <table-wrap id="tab03-body3">
        <graphic xlink:href="1678-4170-abc-92-04-0283-00006-gt03-es.jpg"/></table-wrap>
      <p>Cuando a los individuos que tuvieron eventos hospitalarios se les compararon a los que no tuvieron eventos, la mediana de PCR-us fue semejante en ambos los grupos para ICC (8,1 mg/L <italic>vs. </italic>2,4 mg/L, <italic>p</italic> = 0,47), IAM (7,8 mg/L <italic>vs.</italic> 1,7 mg/L, <italic>p</italic> = 0,81) y muerte por causas cardiovasculares (5,66 mg/L <italic>vs. </italic>2,04 mg/L, <italic>p</italic> = 0,41). No se observ&#243;, asimismo, ninguna diferencia, respectivamente, en la mediana de la IL-6 y del conteo de leucocitos para ICC (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,58; 9.590 l/mm<sup>3</sup> v<italic>s.</italic> 7460 l/mm<sup>3</sup>, <italic>p</italic> = 0,53), IAM (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,58; 7.925 l/mm<sup>3</sup><italic>vs.</italic> 7.860 l/mm<sup>3</sup>, <italic>p</italic> = 0,5) y muerte (0 pg/mL <italic>vs.</italic> 0 pg/mL, <italic>p</italic> = 0,70; 11.500 l/mm<sup>3</sup><italic>vs. </italic>7.900 l/mm<sup>3</sup>, <italic>p</italic> = 0,22).</p>
      <p>No hubo correlaci&#243;n entre el tiempo de hospitalizaci&#243;n y los niveles de PCR-us (r<sub>s</sub> = 0,02, <italic>p</italic> = 0,86), IL-6 (r<sub>s</sub> = 0,09, <italic>p</italic> = 0,44) o conteo de leucocitos (r<sub>s</sub> = 0,21, <italic>p </italic>= 0, 85).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p> Pocos estudios cl&#237;nicos han comparado los marcadores inflamatorios entre pacientes diab&#233;ticos y no-diab&#233;ticos con s&#237;ndrome coronario agudo, pero ninguno de ellos hab&#237;a realizado un estudio exclusivamente con portadores de angina inestable.</p>
      <p>Moreno et al.<sup>18</sup> constataron que el tejido coronario de los pacientes diab&#233;ticos tiene mayor cantidad de ateroma rico en l&#237;pidos, infiltraci&#243;n de macr&#243;fagos y trombosis subsiguiente comparado al tejido de pacientes no-diab&#233;ticos. Esto indica que portadores de diabetes mellitus son m&#225;s vulnerables a la ruptura de la placa y trombosis. Los mismos autores analizaron la patog&#233;nesis de la aterosclerosis diab&#233;tica<sup>19</sup> y creen que los portadores de diabetes mellitus tienen mayor actividad inflamatoria que la poblaci&#243;n en general con aterosclerosis. </p>
      <p>Sin embargo, en este estudio no se observaron diferencias en las concentraciones de PCR-us e IL-6 entre pacientes con angina inestable diab&#233;ticos y no-diab&#233;ticos.</p>
      <p>Aggarwal et al.<sup>13</sup> evaluaron la actividad inflamatoria midi&#233;ndose los niveles de PCR-us en 75 pacientes diab&#233;ticos y no-diab&#233;ticos con s&#237;ndrome coronario agudo antes, durante y tras la colocaci&#243;n de <italic>stent</italic> coronario. Esos autores concluyeron que los pacientes diab&#233;ticos con s&#237;ndrome coronario agudo ten&#237;an mayor actividad inflamatoria antes del procedimiento, pero despu&#233;s de 24 horas no se encontraron diferencias entre los pacientes diab&#233;ticos y no-diab&#233;ticos. Sin embargo, los autores no incluyeron en su metodolog&#237;a informaciones fundamentales que revelaran si la poblaci&#243;n del estudio era, de hecho, portadora de s&#237;ndrome coronario agudo. No se suministraron datos sobre el tiempo transcurrido desde el inicio del dolor tor&#225;cico hasta la internaci&#243;n o hasta aun la colocaci&#243;n de <italic>stent</italic> (primera muestra de sangre). Adem&#225;s de ello, los autores incluyeron solamente a pacientes con angina estable e infarto agudo de miocardio sin supradesnivelaci&#243;n del segmento ST, cuando el factor necrosis puede funcionar como una variable de confusi&#243;n<sup>20</sup>. Asimismo, no se describieron los valores de glucemia, al contrario de nuestro estudio, que utiliz&#243; un criterio validado para definir diabetes.</p>
      <p>El an&#225;lisis de los niveles de PCR entre los dos grupos revel&#243; que, antes de la colocaci&#243;n de <italic>stent</italic>, los pacientes diab&#233;ticos ten&#237;an el doble de actividad inflamatoria de los no-diab&#233;ticos. No obstante, tras la colocaci&#243;n del <italic>stent</italic> coronario (agresi&#243;n endotelial) no hubo diferencia en las concentraciones de PCR-us entre los dos grupos. Gottsauner et al.<sup>21</sup> descubrieron que niveles plasm&#225;ticos elevados de la prote&#237;na C reactiva, que persisten por 96 horas luego de la colocaci&#243;n del<italic> stent</italic>, pueden resultar en una reacci&#243;n inflamatoria prolongada al implante de <italic>stent </italic>coronario.</p>
      <p>El rol de la agresi&#243;n endotelial aguda como est&#237;mulo a una reacci&#243;n inflamatoria intensa tambi&#233;n puede estar presente en la angina inestable, justificando los nuestros hallazgos y reforzando, de esa manera, nuestros resultados.</p>
      <p>Es interesante observar que, en nuestra investigaci&#243;n, utilizamos una metodolog&#237;a bastante atenta para incluir pacientes con angina inestable. Se clasificaron a todos los individuos, de modo riguroso, mediante criterios validados -como angina inestable-, para evitarse la interferencia del factor necrosis como una variable de confusi&#243;n. De ese modo, se internaron en la atenci&#243;n de emergencia cardiaca a los individuos con dolor t&#237;pico y edad promedio superior a los 60 a&#241;os, con una probabilidad posprueba superior al 80 % para SCA. Adem&#225;s de ello, al final del estudio, se confirm&#243; la presencia de enfermedad coronaria ateroscler&#243;tica en el 94% de los pacientes por medio de cineangiocoronariograf&#237;a. Por fin, la homogeneidad entre los grupos se revel&#243; con ausencia de diferencias estad&#237;sticamente significantes, en las caracter&#237;sticas cl&#237;nicas iniciales.</p>
      <p>Nuestros hallazgos con diferencias estad&#237;sticamente significantes (PAS y FC) se pueden explicar por la tendencia de una mayor prevalencia de dolor tor&#225;cico al ingreso en el grupo de pacientes diab&#233;ticos, lo que contrar&#237;a el concepto original<sup>22</sup> que, adem&#225;s, es bastante cuestionado actualmente<sup>23</sup>. </p>
      <p>Sanchez et al.<sup>24</sup>, de lo contrario, observaron que los pacientes diab&#233;ticos con s&#237;ndrome coronario agudo sin supradesnivelaci&#243;n del segmento ST presentaban mayor actividad inflamatoria que los no-diab&#233;ticos. Sin embargo, el conteo de leucocitos de los pacientes diab&#233;ticos fue m&#225;s elevado que el de los no-diab&#233;ticos, y los autores no incluyeron ning&#250;n instrumento para detectar procesos infecciosos asintom&#225;ticos, principalmente en mujeres diab&#233;ticas<sup>25</sup>. En el presente estudio, todos los pacientes fueron sometidos a ex&#225;menes de orina y exploraci&#243;n de las v&#237;as a&#233;reas, inclusive el conducto auditivo, para la exclusi&#243;n de infecciones asintom&#225;ticas. Adem&#225;s de ello, no hubo diferencia en el conteo de leucocitos obtenido a la internaci&#243;n entre pacientes diab&#233;ticos y no-diab&#233;ticos, lo que indica no haber diferencias en el cuadro inflamatorio previo en consecuencia de un proceso infeccioso sist&#233;mico. Sanchez tambi&#233;n no describi&#243; la glucemia al momento de la internaci&#243;n, la glucemia en ayuno y el perfil lip&#237;dico en su estudio.</p>
      <p> Es importante resaltar que el estado metab&#243;lico de diabetes, caracterizado por hiperglucemia y dislipidemia, est&#225; asociado a lesi&#243;n endotelial y, consecuentemente, al aumento en los niveles de los marcadores inflamatorios<sup>19,26,27</sup>.</p>
      <p>Respecto a la correlaci&#243;n positiva entre las concentraciones de PCR-us y el conteo de leucocitos, Danesh et al.<sup>28</sup> describieron una fuerte asociaci&#243;n entre el conteo de leucocitos y el desarrollo de enfermedad arterial coronaria. Stewart et al.<sup>29</sup> observaron una mayor reducci&#243;n de la mortalidad asociada a la utilizaci&#243;n de pravastatina en los pacientes que presentaron valores m&#225;s elevados de conteo de leucocitos a la internaci&#243;n.</p>
      <p>En este estudio, cuando analizamos a todos los pacientes con angina inestable, observamos una correlaci&#243;n d&#233;bil entre la PCR-us y el colesterol total y el colesterol LDL, superior, sin embargo, a la relatada por estudios anteriores<sup>30,31</sup> que no incluyeron a pacientes con s&#237;ndrome coronario agudo.</p>
      <p>No observamos mayor incidencia de desenlaces hospitalarios entre pacientes diab&#233;ticos y no-diab&#233;ticos, a pesar de los datos relatados en la literatura<sup>32</sup>, probablemente en consecuencia del menor per&#237;odo de seguimiento (mediana de 8 d&#237;as) y del peque&#241;o n&#250;mero de pacientes (muestra peque&#241;a) para encontrar m&#225;s desenlaces hospitalarios, como ICC, IAM y muerte (poder reducido) en pacientes con angina inestable.</p>
      <p>Otra limitaci&#243;n de nuestro estudio fue el hecho de que el tiempo promedio entre el inicio del dolor tor&#225;cico y la internaci&#243;n en la atenci&#243;n de emergencia (4 horas), hasta la colecta de las muestras de sangre para medir los niveles de PCR-us, puede haber sido insuficiente para la detecci&#243;n de proceso inflamatorio en marcha. Sin embargo, eso no explicar&#237;a los resultados semejantes de PCR-us entre los dos grupos.</p>
      <p>Nuestros hallazgos indican que los eventos involucrados en un cuadro de s&#237;ndrome coronario agudo, como angina inestable, propician una respuesta inflamatoria importante, sin embargo semejante, entre diab&#233;ticos y no-diab&#233;ticos. Eso nos hace creer que la respuesta inflamatoria resultante de un s&#237;ndrome coronario agudo es m&#225;s intensa y aguda que la respuesta inflamatoria resultante de diabetes, cuyo proceso es m&#225;s lento y continuo y la agresi&#243;n endotelial es duradera. Otra posibilidad es que la utilizaci&#243;n de estatina (que en nuestra investigaci&#243;n se mostr&#243; semejante en pacientes diab&#233;ticos y no-diab&#233;ticos) puede ser m&#225;s eficaz en pacientes diab&#233;ticos, ya que se describi&#243; un efecto antiinflamatorio m&#225;s intenso en individuos con mayor actividad inflamat&#243;ria<sup>29</sup>. Es importante destacar que nuestros pacientes diab&#233;ticos fueron controlados (HbA<sub>1c </sub>promedio = 6,3%) y que ese hallazgo puede disminuir el impacto de hiperglucemia en la agresi&#243;n endotelial.</p>
      <p>Con relaci&#243;n a todos los puntos que discutimos en nuestros estudio, logramos contestar a algunas de la preguntas planteadas al principio. Por ejemplo, &#191; son distintas las caracter&#237;sticas inflamatorias observadas en el diabetes y en el s&#237;ndrome coronario agudo?&#191;Hay alg&#250;n modo de evaluarse eso?&#191;La estatina es m&#225;s eficaz en pacientes diab&#233;ticos que en los no-diab&#233;ticos?&#191;Esa mayor eficacia podr&#237;a explicar la igualdad de la actividad inflamatoria entre los grupos con s&#237;ndrome coronario agudo incluidos en el estudio?&#191;Es la reacci&#243;n inflamatoria en el s&#237;ndrome coronario agudo tan intensa que podr&#237;a equilibrar la actividad inflamatoria de los pacientes diab&#233;ticos y no-diab&#233;ticos?</p>
      <p>Nuestros hallazgos nos permiten concluir que la actividad inflamatoria es semejante en pacientes diab&#233;ticos y no-diab&#233;ticos con angina inestable. En esos pacientes, la PCR-us present&#243; una correlaci&#243;n positiva con el colesterol total y LDL, as&#237; como con el conteo de leucocitos. Esos hallazgos resaltan a&#250;n la importancia de la PCR como un marcador de agresi&#243;n endotelial en el s&#237;ndrome coronario agudo, as&#237; como el aspecto multifactorial del proceso de aterotrombosis. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por la Fundaci&#243;n de Amparo a la Investigaci&#243;n del Estado de Bahia (FAPESB).</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de disertaci&#243;n de Maestr&#237;a de Mar&#231;al de Oliveira Huoya, por la Escuela Bahiana de Medicina y Salud P&#250;blica-FBDC.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
